US20010014673A1 - Live vaccine against brucellosis - Google Patents
Live vaccine against brucellosis Download PDFInfo
- Publication number
- US20010014673A1 US20010014673A1 US09/010,877 US1087798A US2001014673A1 US 20010014673 A1 US20010014673 A1 US 20010014673A1 US 1087798 A US1087798 A US 1087798A US 2001014673 A1 US2001014673 A1 US 2001014673A1
- Authority
- US
- United States
- Prior art keywords
- brucella
- dna
- rfbu
- deletion
- brucellosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 55
- 206010006500 Brucellosis Diseases 0.000 title claims abstract description 29
- 241000589562 Brucella Species 0.000 claims abstract description 85
- 238000012217 deletion Methods 0.000 claims abstract description 65
- 230000037430 deletion Effects 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 40
- 101150048342 rfbU gene Proteins 0.000 claims abstract description 27
- 108020004414 DNA Proteins 0.000 claims description 76
- 101100248159 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) rfbU gene Proteins 0.000 claims description 41
- 208000015181 infectious disease Diseases 0.000 claims description 29
- 241001148106 Brucella melitensis Species 0.000 claims description 27
- 230000002238 attenuated effect Effects 0.000 claims description 25
- 239000013598 vector Substances 0.000 claims description 25
- 239000002773 nucleotide Substances 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 18
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 238000009396 hybridization Methods 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 108020004511 Recombinant DNA Proteins 0.000 claims description 12
- 238000003752 polymerase chain reaction Methods 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 229940038698 brucella melitensis Drugs 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 8
- 102000040430 polynucleotide Human genes 0.000 claims description 8
- 239000002157 polynucleotide Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000003745 diagnosis Methods 0.000 claims description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 6
- -1 nucleotide triphosphates Chemical class 0.000 claims description 5
- 239000001226 triphosphate Substances 0.000 claims description 4
- 235000011178 triphosphate Nutrition 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 2
- 101150019467 purE gene Proteins 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 1
- 230000009851 immunogenic response Effects 0.000 abstract description 5
- 230000001681 protective effect Effects 0.000 abstract 2
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 23
- 239000000427 antigen Substances 0.000 description 19
- 108091007433 antigens Proteins 0.000 description 19
- 102000036639 antigens Human genes 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 239000008272 agar Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 210000000349 chromosome Anatomy 0.000 description 13
- 238000003780 insertion Methods 0.000 description 13
- 230000037431 insertion Effects 0.000 description 13
- 229960005091 chloramphenicol Drugs 0.000 description 12
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 241000589567 Brucella abortus Species 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 239000013615 primer Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000003115 biocidal effect Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000274793 Brucella melitensis bv. 1 str. 16M Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 235000008612 Gnetum gnemon Nutrition 0.000 description 5
- 240000000018 Gnetum gnemon Species 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 230000004520 agglutination Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000032 diagnostic agent Substances 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000004980 monocyte derived macrophage Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229940056450 brucella abortus Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- OQPAZKMGCWPERI-GUBZILKMSA-N Arg-Ser-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OQPAZKMGCWPERI-GUBZILKMSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102000006722 Mannosyltransferases Human genes 0.000 description 2
- 108010087568 Mannosyltransferases Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241001138501 Salmonella enterica Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108010056582 methionylglutamic acid Proteins 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- KQESEZXHYOUIIM-CQDKDKBSSA-N Ala-Lys-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O KQESEZXHYOUIIM-CQDKDKBSSA-N 0.000 description 1
- ZBLQIYPCUWZSRZ-QEJZJMRPSA-N Ala-Phe-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](C)N)CC1=CC=CC=C1 ZBLQIYPCUWZSRZ-QEJZJMRPSA-N 0.000 description 1
- BHTBAVZSZCQZPT-GUBZILKMSA-N Ala-Pro-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N BHTBAVZSZCQZPT-GUBZILKMSA-N 0.000 description 1
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 1
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 1
- IYKVSFNGSWTTNZ-GUBZILKMSA-N Ala-Val-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IYKVSFNGSWTTNZ-GUBZILKMSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BEXGZLUHRXTZCC-CIUDSAMLSA-N Arg-Gln-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N BEXGZLUHRXTZCC-CIUDSAMLSA-N 0.000 description 1
- ZJEDSBGPBXVBMP-PYJNHQTQSA-N Arg-His-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZJEDSBGPBXVBMP-PYJNHQTQSA-N 0.000 description 1
- YKZJPIPFKGYHKY-DCAQKATOSA-N Arg-Leu-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKZJPIPFKGYHKY-DCAQKATOSA-N 0.000 description 1
- OISWSORSLQOGFV-AVGNSLFASA-N Arg-Met-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CCCN=C(N)N OISWSORSLQOGFV-AVGNSLFASA-N 0.000 description 1
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 1
- ZUVMUOOHJYNJPP-XIRDDKMYSA-N Arg-Trp-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZUVMUOOHJYNJPP-XIRDDKMYSA-N 0.000 description 1
- XMZZGVGKGXRIGJ-JYJNAYRXSA-N Arg-Tyr-Val Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O XMZZGVGKGXRIGJ-JYJNAYRXSA-N 0.000 description 1
- NXVGBGZQQFDUTM-XVYDVKMFSA-N Asn-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC(=O)N)N NXVGBGZQQFDUTM-XVYDVKMFSA-N 0.000 description 1
- ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N Asn-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N 0.000 description 1
- XXAOXVBAWLMTDR-ZLUOBGJFSA-N Asn-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N XXAOXVBAWLMTDR-ZLUOBGJFSA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- SPCONPVIDFMDJI-QSFUFRPTSA-N Asn-Ile-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O SPCONPVIDFMDJI-QSFUFRPTSA-N 0.000 description 1
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 description 1
- RCFGLXMZDYNRSC-CIUDSAMLSA-N Asn-Lys-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O RCFGLXMZDYNRSC-CIUDSAMLSA-N 0.000 description 1
- QUCCLIXMVPIVOB-BZSNNMDCSA-N Asn-Tyr-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N QUCCLIXMVPIVOB-BZSNNMDCSA-N 0.000 description 1
- MYRLSKYSMXNLLA-LAEOZQHASA-N Asn-Val-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O MYRLSKYSMXNLLA-LAEOZQHASA-N 0.000 description 1
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
- WSGVTKZFVJSJOG-RCOVLWMOSA-N Asp-Gly-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O WSGVTKZFVJSJOG-RCOVLWMOSA-N 0.000 description 1
- MYOHQBFRJQFIDZ-KKUMJFAQSA-N Asp-Leu-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYOHQBFRJQFIDZ-KKUMJFAQSA-N 0.000 description 1
- PCJOFZYFFMBZKC-PCBIJLKTSA-N Asp-Phe-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PCJOFZYFFMBZKC-PCBIJLKTSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241001495160 Brucella abortus bv. 1 Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 101710117490 Circumsporozoite protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- NMWZMKLDGZXRKP-BZSNNMDCSA-N Cys-Phe-Phe Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NMWZMKLDGZXRKP-BZSNNMDCSA-N 0.000 description 1
- TXGDWPBLUFQODU-XGEHTFHBSA-N Cys-Pro-Thr Chemical compound [H]N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O TXGDWPBLUFQODU-XGEHTFHBSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- KVYVOGYEMPEXBT-GUBZILKMSA-N Gln-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O KVYVOGYEMPEXBT-GUBZILKMSA-N 0.000 description 1
- MGJMFSBEMSNYJL-AVGNSLFASA-N Gln-Asn-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MGJMFSBEMSNYJL-AVGNSLFASA-N 0.000 description 1
- IKFZXRLDMYWNBU-YUMQZZPRSA-N Gln-Gly-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N IKFZXRLDMYWNBU-YUMQZZPRSA-N 0.000 description 1
- NYCVMJGIJYQWDO-CIUDSAMLSA-N Gln-Ser-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NYCVMJGIJYQWDO-CIUDSAMLSA-N 0.000 description 1
- OACPJRQRAHMQEQ-NHCYSSNCSA-N Gln-Val-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OACPJRQRAHMQEQ-NHCYSSNCSA-N 0.000 description 1
- PHONAZGUEGIOEM-GLLZPBPUSA-N Glu-Glu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PHONAZGUEGIOEM-GLLZPBPUSA-N 0.000 description 1
- MTAOBYXRYJZRGQ-WDSKDSINSA-N Glu-Gly-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MTAOBYXRYJZRGQ-WDSKDSINSA-N 0.000 description 1
- LHIPZASLKPYDPI-AVGNSLFASA-N Glu-Phe-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O LHIPZASLKPYDPI-AVGNSLFASA-N 0.000 description 1
- ARIORLIIMJACKZ-KKUMJFAQSA-N Glu-Pro-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ARIORLIIMJACKZ-KKUMJFAQSA-N 0.000 description 1
- YQAQQKPWFOBSMU-WDCWCFNPSA-N Glu-Thr-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O YQAQQKPWFOBSMU-WDCWCFNPSA-N 0.000 description 1
- KIEICAOUSNYOLM-NRPADANISA-N Glu-Val-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O KIEICAOUSNYOLM-NRPADANISA-N 0.000 description 1
- RMWAOBGCZZSJHE-UMNHJUIQSA-N Glu-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N RMWAOBGCZZSJHE-UMNHJUIQSA-N 0.000 description 1
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 1
- HFXJIZNEXNIZIJ-BQBZGAKWSA-N Gly-Glu-Gln Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFXJIZNEXNIZIJ-BQBZGAKWSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- YTSVAIMKVLZUDU-YUMQZZPRSA-N Gly-Leu-Asp Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YTSVAIMKVLZUDU-YUMQZZPRSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- WNGHUXFWEWTKAO-YUMQZZPRSA-N Gly-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN WNGHUXFWEWTKAO-YUMQZZPRSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- DZMVESFTHXSSPZ-XVYDVKMFSA-N His-Ala-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DZMVESFTHXSSPZ-XVYDVKMFSA-N 0.000 description 1
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 1
- NBJAAWYRLGCJOF-UGYAYLCHSA-N Ile-Asp-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N NBJAAWYRLGCJOF-UGYAYLCHSA-N 0.000 description 1
- RGSOCXHDOPQREB-ZPFDUUQYSA-N Ile-Asp-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N RGSOCXHDOPQREB-ZPFDUUQYSA-N 0.000 description 1
- CKRFDMPBSWYOBT-PPCPHDFISA-N Ile-Lys-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N CKRFDMPBSWYOBT-PPCPHDFISA-N 0.000 description 1
- JODPUDMBQBIWCK-GHCJXIJMSA-N Ile-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O JODPUDMBQBIWCK-GHCJXIJMSA-N 0.000 description 1
- WLRJHVNFGAOYPS-HJPIBITLSA-N Ile-Ser-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N WLRJHVNFGAOYPS-HJPIBITLSA-N 0.000 description 1
- BQIIHAGJIYOQBP-YFYLHZKVSA-N Ile-Trp-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@@H]3C(=O)O)N BQIIHAGJIYOQBP-YFYLHZKVSA-N 0.000 description 1
- YJRSIJZUIUANHO-NAKRPEOUSA-N Ile-Val-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)O)N YJRSIJZUIUANHO-NAKRPEOUSA-N 0.000 description 1
- KXUKTDGKLAOCQK-LSJOCFKGSA-N Ile-Val-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O KXUKTDGKLAOCQK-LSJOCFKGSA-N 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- OYQUOLRTJHWVSQ-SRVKXCTJSA-N Leu-His-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O OYQUOLRTJHWVSQ-SRVKXCTJSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 1
- YIBOAHAOAWACDK-QEJZJMRPSA-N Lys-Ala-Phe Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 YIBOAHAOAWACDK-QEJZJMRPSA-N 0.000 description 1
- MKBIVWXCFINCLE-SRVKXCTJSA-N Lys-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCCN)N MKBIVWXCFINCLE-SRVKXCTJSA-N 0.000 description 1
- CKSBRMUOQDNPKZ-SRVKXCTJSA-N Lys-Gln-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O CKSBRMUOQDNPKZ-SRVKXCTJSA-N 0.000 description 1
- VQXAVLQBQJMENB-SRVKXCTJSA-N Lys-Glu-Met Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O VQXAVLQBQJMENB-SRVKXCTJSA-N 0.000 description 1
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 1
- NKKFVJRLCCUJNA-QWRGUYRKSA-N Lys-Gly-Lys Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN NKKFVJRLCCUJNA-QWRGUYRKSA-N 0.000 description 1
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 1
- NYTDJEZBAAFLLG-IHRRRGAJSA-N Lys-Val-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O NYTDJEZBAAFLLG-IHRRRGAJSA-N 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- ULNXMMYXQKGNPG-LPEHRKFASA-N Met-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCSC)N ULNXMMYXQKGNPG-LPEHRKFASA-N 0.000 description 1
- PJWDQHNOJIBMRY-JYJNAYRXSA-N Met-Arg-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PJWDQHNOJIBMRY-JYJNAYRXSA-N 0.000 description 1
- MTBVQFFQMXHCPC-CIUDSAMLSA-N Met-Glu-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MTBVQFFQMXHCPC-CIUDSAMLSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- 101100205189 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-5 gene Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- BJEYSVHMGIJORT-NHCYSSNCSA-N Phe-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BJEYSVHMGIJORT-NHCYSSNCSA-N 0.000 description 1
- FPTXMUIBLMGTQH-ONGXEEELSA-N Phe-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 FPTXMUIBLMGTQH-ONGXEEELSA-N 0.000 description 1
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 description 1
- VHWOBXIWBDWZHK-IHRRRGAJSA-N Phe-Arg-Asp Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 VHWOBXIWBDWZHK-IHRRRGAJSA-N 0.000 description 1
- MGECUMGTSHYHEJ-QEWYBTABSA-N Phe-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 MGECUMGTSHYHEJ-QEWYBTABSA-N 0.000 description 1
- HQPWNHXERZCIHP-PMVMPFDFSA-N Phe-Leu-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 HQPWNHXERZCIHP-PMVMPFDFSA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- GDXZRWYXJSGWIV-GMOBBJLQSA-N Pro-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 GDXZRWYXJSGWIV-GMOBBJLQSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- BODDREDDDRZUCF-QTKMDUPCSA-N Pro-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]2CCCN2)O BODDREDDDRZUCF-QTKMDUPCSA-N 0.000 description 1
- IBGCFJDLCYTKPW-NAKRPEOUSA-N Pro-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 IBGCFJDLCYTKPW-NAKRPEOUSA-N 0.000 description 1
- SOACYAXADBWDDT-CYDGBPFRSA-N Pro-Ile-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SOACYAXADBWDDT-CYDGBPFRSA-N 0.000 description 1
- AQGUSRZKDZYGGV-GMOBBJLQSA-N Pro-Ile-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O AQGUSRZKDZYGGV-GMOBBJLQSA-N 0.000 description 1
- KLOQCCRTPHPIFN-DCAQKATOSA-N Pro-Met-Gln Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@@H]1CCCN1 KLOQCCRTPHPIFN-DCAQKATOSA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- RNEFESSBTOQSAC-DCAQKATOSA-N Pro-Ser-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O RNEFESSBTOQSAC-DCAQKATOSA-N 0.000 description 1
- IIRBTQHFVNGPMQ-AVGNSLFASA-N Pro-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1 IIRBTQHFVNGPMQ-AVGNSLFASA-N 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- XVWDJUROVRQKAE-KKUMJFAQSA-N Ser-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=CC=C1 XVWDJUROVRQKAE-KKUMJFAQSA-N 0.000 description 1
- IAOHCSQDQDWRQU-GUBZILKMSA-N Ser-Val-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IAOHCSQDQDWRQU-GUBZILKMSA-N 0.000 description 1
- 101100309436 Streptococcus mutans serotype c (strain ATCC 700610 / UA159) ftf gene Proteins 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- LXWZOMSOUAMOIA-JIOCBJNQSA-N Thr-Asn-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O LXWZOMSOUAMOIA-JIOCBJNQSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 description 1
- WNQJTLATMXYSEL-OEAJRASXSA-N Thr-Phe-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O WNQJTLATMXYSEL-OEAJRASXSA-N 0.000 description 1
- SJPDTIQHLBQPFO-VLCNGCBASA-N Thr-Tyr-Trp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O SJPDTIQHLBQPFO-VLCNGCBASA-N 0.000 description 1
- ILUOMMDDGREELW-OSUNSFLBSA-N Thr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O ILUOMMDDGREELW-OSUNSFLBSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- NXJZCPKZIKTYLX-XEGUGMAKSA-N Trp-Glu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N NXJZCPKZIKTYLX-XEGUGMAKSA-N 0.000 description 1
- IMYTYAWRKBYTSX-YTQUADARSA-N Trp-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CNC4=CC=CC=C43)N)C(=O)O IMYTYAWRKBYTSX-YTQUADARSA-N 0.000 description 1
- WMBFONUKQXGLMU-WDSOQIARSA-N Trp-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WMBFONUKQXGLMU-WDSOQIARSA-N 0.000 description 1
- AKXBNSZMYAOGLS-STQMWFEESA-N Tyr-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AKXBNSZMYAOGLS-STQMWFEESA-N 0.000 description 1
- NLMXVDDEQFKQQU-CFMVVWHZSA-N Tyr-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLMXVDDEQFKQQU-CFMVVWHZSA-N 0.000 description 1
- UBKKNELWDCBNCF-STQMWFEESA-N Tyr-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 UBKKNELWDCBNCF-STQMWFEESA-N 0.000 description 1
- BGFCXQXETBDEHP-BZSNNMDCSA-N Tyr-Phe-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O BGFCXQXETBDEHP-BZSNNMDCSA-N 0.000 description 1
- ARMNWLJYHCOSHE-KKUMJFAQSA-N Tyr-Pro-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O ARMNWLJYHCOSHE-KKUMJFAQSA-N 0.000 description 1
- NAHUCETZGZZSEX-IHPCNDPISA-N Tyr-Trp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NAHUCETZGZZSEX-IHPCNDPISA-N 0.000 description 1
- GOPQNCQSXBJAII-ULQDDVLXSA-N Tyr-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N GOPQNCQSXBJAII-ULQDDVLXSA-N 0.000 description 1
- KKHRWGYHBZORMQ-NHCYSSNCSA-N Val-Arg-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKHRWGYHBZORMQ-NHCYSSNCSA-N 0.000 description 1
- XPYNXORPPVTVQK-SRVKXCTJSA-N Val-Arg-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCSC)C(=O)O)N XPYNXORPPVTVQK-SRVKXCTJSA-N 0.000 description 1
- XGJLNBNZNMVJRS-NRPADANISA-N Val-Glu-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O XGJLNBNZNMVJRS-NRPADANISA-N 0.000 description 1
- PMXBARDFIAPBGK-DZKIICNBSA-N Val-Glu-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PMXBARDFIAPBGK-DZKIICNBSA-N 0.000 description 1
- DJQIUOKSNRBTSV-CYDGBPFRSA-N Val-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](C(C)C)N DJQIUOKSNRBTSV-CYDGBPFRSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 description 1
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 1
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000003167 genetic complementation Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000309465 heifer Species 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000013120 recombinational repair Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 238000012106 screening analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
- 108010005834 tyrosyl-alanyl-glycine Proteins 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010015385 valyl-prolyl-proline Proteins 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/23—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Brucella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- Brucella infects a significant number of people and livestock in developing countries and infects wild as well as domestic animals in the United States.
- Brucella is a potential biowarfare agent; strains of Brucella have been constructed with resistance to multiple antibiotics used to treat the disease. These strains pose a significant morbidity and mortality threat to exposed personnel.
- Brucellosis symptoms include recurring fever, chills and anxiety. Even though the disease is rarely fatal, once well established, the disease is difficult to treat since the bacteria reside in the bone marrow.
- RB51 is a rough strain that confers protection against infection by Brucella, yet does not cause seroconversion [Cheville, N. F. 1993, supra; Jimenez de Bagues, M. P. et al. (1994) Infect. Immun. 62:4990-4996].
- RB51 carries resistance to rifampin, an antibiotic currently used to treat brucellosis.
- the present invention fulfills the need described above.
- attenuated rough strains of Brucella containing genetically defined mutations, which will not cause seroconversion.
- the mutations in these attenuated Brucella strains were created by DNA deletion, the type of mutation least susceptible to genetic reversion and are therefore advantageous as vaccine strains. These vaccines strains do not retain resistance to an antibiotic useful for treatment of brucellosis.
- this invention relates to two genetically defined rough mutants of Brucella melitensis , WRR51 and WRRP1, as candidate strains for a live vaccine against brucellosis.
- WRR51 and WRRP1 differ from Brucella live vaccines currently used in livestock because they have genetically defined mutations that were created by deleting DNA from the Brucella chromosome.
- Both strains have a lipopolysaccharide (LPS) defect and thus do not cause the seroconversion that complicates disease screening.
- Smooth strains currently approved for use in animals are not good candidates for human vaccines because though attenuated, they can still cause disease in humans.
- One of the vaccine strains of the present invention, WRRP1 is a double deletion mutant that is highly attenuated and is unlikely to cause disease in humans.
- the genetically defined rough mutants of Brucella were constructed by using a Brucella abortus VTRA1 chromosome containing a Tn5 insertion which conferred a rough phenotype [Winter, A. J. et al. (1996) Amer. J. Vet. Res. 57:677-683].
- the B. abortus gene containing the Tn5 insertion was cloned from the VTRA1 chromosome and the nucleotide sequence of the 2693 bp (SEQ ID NO:1) region containing the transposon insertion was determined.
- the Tn5 insertion was found to be located within an open reading frame of 1233 bp spanning nucleotides 883 through 2115 of SEQ ID NO:1 which coded for a gene that was distantly related (40% amino acid similarity) to the sequence of the Salmonella enterica LT2 rfbU, a gene encoding a mannosyltransferase [Liu, D. et al. (1993) J. Bacteriol. 175:3408-2414].
- a deletion of 607 bp was made in the putative rfbU gene and a cassette containing a chloramphenicol acetyl transferase gene (cat) was ligated into the deletion site to create rfbU/cat.
- the plasmid containing rfbU/cat, pRFBU1 was electroporated into B. melitensis strain 16M and electroporants with pRFBU1 integrated were selected on Brucella agar containing chloramphenicol. Southern DNA hybridization confirmed that the chloramphenicol resistant and ampicillin sensitive electroporants had the deletion mutation carrying the chloramphenicol resistance cassette in place of the wild type chromosomal locus resulting from a directed allelic exchange by a double crossover recombinational event.
- the deletion strain, designated WRR51 was confirmed to be rough by staining with crystal violet, and by lack of agglutination with an anti-LPS serum.
- a purE deletion was then introduced into B. melitensis strain WRR51 by a similar allelic exchange procedure.
- PurE is an essential enzyme in the purine biosynthetic pathway.
- the resultant double deletion strain ( ⁇ rfbU ⁇ purE) was designated WRRP1.
- the DNA flanking the transposon insertion was sequenced to determine the open reading frame that had been interrupted to cause the rough phenotype and was found to be rfbU.
- the complete sequence of Brucella rfbU is described for the first time in this application in SEQ ID NO:1.
- mutant strains were produced by a transposon insertion which is a random event and can occur at any chromosomal location wherein the mutants of the present invention were produced by a directed allelic exchange to produce a unrevertable, defined deletion in the gene.
- a plasmid construct containing a synthetic copy of the putative rfbU gene that restored the smooth phenotype to the WRR51 deletion mutant of the present invention did not restore the smooth phenotype to the VTRA1 transposon mutant.
- the inability to complement the transposon mutant indicates either that the transposon insertion confers a more general genetic defect in LPS biosynthesis (via a polar effect), or that the VTRA1 strain has additional mutations that affect LPS biosynthesis.
- the rough mutants of the present invention have a defined, nonreverting, deletion in the putative rfbU gene that was integrated into the chromosome by allelic exchange.
- flanking DNA the rfbU gene
- the sequence of the flanking DNA had to be known to allow for PCR or direct cloning of a large enough region of the Brucella chromosome.
- All of the Brucella which infect humans are highly related, probably biovars of the same species [Corbel, M. J. (1997) Emerging Inf. Dis. 3:213-221]. It is expected that this live vaccine would provide cross protection against other Brucella strains since there is thought to be high homology in the rfbU gene in brucellae [Jimenez de Bagues, M. P. et al. (1994) Infect. and Immun. 62:4990-4996].
- RfbU is usually either cytoplasmic or associated with the inner membrane. When brucellae are lysed within host cells, RfbU and any antigen designed to be expressed with RfbU would then be accessible to the intracellular environment of the cell or host.
- the attenuated Brucella of the present invention can be used in producing inactivated Brucella vaccines.
- an attenuated Brucella particularly the double mutant which is significantly attenuated, there is a much greater margin of safety in the event that the product is incompletely inactivated.
- Starting with an attenuated strain is also much safer during the manufacturing phase, and may allow production under lower biocontainment levels.
- inactivated attenuated Brucella strains can be used to isolate subunits for subunit vaccines.
- FIG. 1 shows ability of rough mutants to grow within human host cells.
- FIG. 2 shows the ability of rough mutants to infect mice via the intraperitoneal route.
- the present invention relates to a DNA or cDNA segment which encodes RfbU, a mannosyltransferase.
- the sequence of the gene, specified in SEQ ID NO:1 was obtained by cloning out a Brucella abortus VTRA1 chromosome containing a Tn5 transposon and sequencing the subclones to determine the insertion site of Tn5 in the VTRA1 chromosome.
- the sequenced gene fragment comprising 2693 base pairs contains an open reading frame of 1233 base pairs.
- DNA or polynucleotide sequences to which the invention also relates include sequences of at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, most preferably at least about 15-20 nucleotides corresponding, i.e., homologous to or complementary to, a region of the rfbU nucleotide sequence.
- the sequence of the region from which the polynucleotide is derived is homologous to or complementary to a sequence which is unique to the rfbU gene. Whether or not a sequence is unique to the rfbU gene can be determined by techniques known to those of skill in the art.
- sequences in databanks e.g., GenBank and compared by DNA:DNA hybridization.
- Regions from which typical DNA sequences may be derived include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non-translated regions.
- DNA sequences also embodied in the present invention include the rfbU sequence containing a deletion.
- the exemplified deletion described below in the Examples is 607 base pairs in length, spanning from position 1063 to position 1670 of the DNA sequence identified in SEQ. ID. NO:1 and was chosen because of conveniently located restriction sites.
- Other deletions of any size can be introduced into the rfbU gene for different purposes.
- RfbU function is to be eliminated
- a deletion large enough to eliminate any possibility of recombinational restoration of gene function is preferable.
- the deletion need not be framed by restriction sites and can be introduced by PCR, for example. However, cloned homologous DNA of about 500 base pairs flanking the deletion site is necessary for efficient allelic replacement.
- the derived polynucleotide is not necessarily physically derived from the nucleotide sequence shown in SEQ ID NO:1, but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription, which are based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived.
- combinations of regions corresponding to that of the designated sequence may be modified in ways known in the art to be consistent with an intended use.
- the sequences of the present invention can be used in diagnostic assays such as hybridization assays and polymerase chain reaction assays and for the discovery of other rfbU sequences.
- the present invention relates to a recombinant DNA molecule that includes a vector and a DNA sequence as described above.
- the vector can take the form of a plasmid, such as pUC19, or any other vector which replicates in E. coli , or a suicide vector, or broad host range vectors for example pTh10(IncP), pSa(IncW) and R751(IncP) [Rigby, C. E. and A. D. E. Fraser (1989) Can. J. Vet. Res. 53:326-330] and others known in the art.
- the present invention relates to host cells stably transformed or transfected with the above-described recombinant DNA constructs.
- the host cell can be any Brucella or other host cell for which the vector is designed.
- the vector containing the rfbU gene is expressed in the bacteria and the product can be isolated for use in diagnostic assays.
- the plasmid pRFBU1 described below in Materials and Methods, containing the rfbU/cat construct can be electroporated into other brucellae, and by allelic exchange with the wild type form of rfbU, can attenuate the electroporants.
- the DNA sequence can be present in the vector operably linked to a highly purified IgG molecule, an adjuvant, a carrier, or an agent for aid in purification of RfbU protein.
- the transformed or transfected host cells can be used as a source of DNA sequences described above.
- the recombinant molecule takes the form of an expression system, the transformed or transfected cells can be used as a source of the protein described below.
- the present invention relates to a RfbU protein having an amino acid sequence corresponding to SEQ ID NO:2 and encompassing 411 amino acids or any allelic variation thereof.
- a polypeptide or amino acid sequence derived from the amino acid sequence in SEQ ID NO:2 refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 2-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.
- a recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence, or the sequence in SEQ ID NO:1; it may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system.
- the polypeptide can be fused to other proteins or polypeptides for example, any protective antigen of any pathogen, bacterial or viral for secretion of heterologous antigens from within the host cell since RfbU is either cytoplasmic or associated with the inner membrane.
- the protein or polypeptide can be fused to other proteins or polypeptides which increase its antigenicity, thereby producing higher titers of neutralizing antibody when used as a vaccine. Examples of such proteins or polypeptides include any adjuvants or carriers safe for human use, such as aluminum hydroxide.
- the present invention relates to antibodies specific for the above-described RfbU protein.
- an antibody can be raised against the complete RfbU protein or against a portion thereof.
- Persons with ordinary skill in the art using standard methodology can raise monoclonal and polyclonal antibodies to the polypeptide of the present invention. Material and methods for producing antibodies are well known in the art (see for example Goding, in, Monoclonal Antibodies: Principles and Practice , Chapter 4, 1986).
- the present invention relates to a method for detecting the presence of brucellosis infection or antibodies against Brucella in a sample.
- a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), all or a unique portion of the RfbU protein, or alternatively, inactivated attenuated Brucella described above, and contacting it with the serum of a person suspected of having a brucellosis infection.
- the presence of a resulting complex formed between the antigen (RfbU or attenuated Brucella) and antibodies specific therefor in the serum can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colorimetry. This method of detection can be used, for example, for the diagnosis and typing of brucellosis infections.
- the present invention relates to a method of detecting the presence of Brucella in a sample.
- a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), antibodies specific for RfbU, and contacting it with serum or tissue sample of a person suspected of having a brucellosis infection.
- the presence or absence of a resulting complex formed between RfbU in the serum or presented on antigen presenting cells and antibodies specific therefor can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colorimetry.
- This method of detection can be used, for example, for the diagnosis of a brucellosis infection or for typing the specific Brucella bacteria causing such an infection.
- the present invention relates to a diagnostic kit which contains RfbU from a specific strain or species of Brucella or several different strains and species of Brucella and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence of antibodies to Brucella in serum or a tissue sample.
- Tissue, blood, serum, or urine samples contemplated can be animal, in particular abortion products of large animals, or human, or other vertebrates. Other samples contemplated include dairy products, especially unpasturized products, from which the disease is most frequently contracted.
- the present invention relates to DNA or nucleotide sequences for use in detecting the presence or absence of Brucella using the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- the DNA sequence of the present invention can be used to design primers which specifically bind to the rfbU DNA for the purpose of detecting the presence, absence, or quantitating the amount of Brucella.
- the primers can be any length ranging from 7-40 nucleotides, preferably 10-15 nucleotides, most preferably 18-25 nucleotides. Reagents and controls necessary for PCR reactions are well known in the art.
- the amplified products can then be analyzed for the presence or absence of rfbU sequences, for example by gel fractionation, with or without hyridization, by radiochemistry, and immunochemical techniques. This method can also be used for typing a brucellosis infection.
- the present invention relates to a diagnostic kit which contains PCR primers specific for rfbU, and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence or absence of Brucella in a sample using PCR.
- Samples contemplated can be human or other mammals, dairy products, blood, urine, tissues, depending on the stage of infection. Early infection tissues would include lungs and the lymphatic system, late infection tissues would include spleen, liver, and kidneys, and later infection tissues would include bone marrow and absesses in organs and brain.
- the present invention can be used to diagnose Brucella infection by using the DNA sequences for detecting the presence or absence of rfbU in a DNA sample using hybridization assays such as Southern hybridization or the expression of rfbU gene, or rfbU RNA, by northern hybridizations and other hybridization assays well known to a person with ordinary skill in the art.
- hybridization assays such as Southern hybridization or the expression of rfbU gene, or rfbU RNA
- the present invention relates to a vaccine for protection against infections by Brucella.
- the vaccine comprises one or more attenuated rough Brucella strains containing a defined deletion, for example, in the rfbU gene.
- the deletion in the rfbU gene can be introduced by allelic exchange due to a double cross-over recombinational event, or any other method wherein a DNA replacement event in which two separate DNA recombination events result in the exchange of a piece of the intact gene for a homologous piece containing a deletion.
- the deletion is preferably large enough such that the gene is inactivated in the first attempt and to reduce the likelihood of a recombinational repair.
- genes which can be deleted include purE, dnaKJ, recA, groELS, catalase, or any other gene which contributes to survival in human macrophages and/or to bacterial virulence.
- Any strain of Brucella can be used to introduce such an attenuating mutation.
- the resulting attenuated strain can be tested for the deletion of the targetted gene by methods known in the art such as Southern blot hybridization, and the level of attenuation tested in a mouse model as described in the Examples below. Any deletion in the rfbU gene would result in the attenuation of the bacteria unless the deletion was small and allowed for functional rfbU expression. Any deletion which inactivates the rfbU gene expression or blocks function of its gene product will be both rough and attenuated.
- a deletion in the rfbU gene of Brucella melitensis was introduced by allelic exchange with a copy of the rfbU gene present on a vector.
- the rfbU gene to be exchanged with the wild type version contained a deletion into which a chloramphenicol acetyl transferase gene was cloned.
- a double cross-over recombinational event occured such that the vector rfbU gene containing the deletion, was exchanged for the chromosomal wild type rfbU.
- the resulting B. melitensis strain WRR51 contained a defined mutation was rough and attenuated, and did not possess resistance to an antibiotic used to treat brucellosis.
- the Brucella having the deletion in the rfbU gene as described above additionally contains another deletion in a different gene.
- the advantage of having two deletions is to further reduce the possibility of reversion, and to additionally attenuate the bacteria.
- any vaccine strain designed in the methods of the present invention must be tested for its ability to survive in the host. These tests can be done in vitro, for example in a monocyte-derived macrophages system as described below in the Examples, or, as a second step, in non-human primates. It is preferable that the bacteria persists in the host for sufficient time to elicit a strong immunogenic response, for example from about four to six weeks. Bacteria too attenuated to survive enough to elicit an immunogenic response can be useful as diagnostic agents.
- a deletion in the purE gene of B. melitensis WRR51 was introduced using the allelic exchange procedure described above.
- the wild type purE locus was replaced with a deleted allele with a kanamycin resistance cassette inserted in the deletion site.
- the resultant double deletion strain ( ⁇ rfbU ⁇ purE) was designated WRRP1.
- Other genes which can be used for introducing a second deletion include, but are not limited to e.g.
- dnaKJ, recA genes potentially contributing to intracellular survival and proliferation (replication), for example by studying genes homologous to those found important in other intracellular bacterial pathogens or by screening for important genes for brucellar intracellular survival directly using IVET, or in vivo expression technology [Mahan, M. J. et al. (1993) Science 259:686-688].
- Both the single deletion strain, WRR51, and the double deletion strain, WRRP1 were tested in human-derived macrophages and were found able to infect human monocytes, and had reduced capacity to grow within host cells.
- WRRP1 the double deletion, appeared to lose viability in host cells at a more rapid rate than those with a single deletion mutation such as WRR51, ( ⁇ rfbU), or B. melitensis ⁇ purE.
- the subject strains should be able to persist in the host for extended periods of time, usually weeks, to enhance the effectiveness of the immunizing effect by continuous stimulation of the host immmune system until the host immune system has cleared all the organisms.
- the vaccine strains should be sensitive to all antibiotics and synthetic antibacterials which are active against strains of Brucella. Even though strains containing these markers can be used as animal vaccines, it is preferable that strains selected on the basis of a selectable markers such as cat or kanamycin be further manipulated to remove these selectable markers. Methods for removing the marker gene include use of a “toxic” gene in vector as counterselectable marker to insure double crossover event e.g. sacB. These markers would be removed by a second allelic exchange, homologous recombination, this time with a copy of the gene containing the same deletion, but without the antibiotic resistance cassette inserted and verified by phenotype screening and Southern blot analysis. It is preferable to avoid providing resistance genes that can be disseminated through the environment or within the host to other pathogens.
- the subject vaccines may be used in a wide variety of vertebrates.
- the subject vaccines will find particular use with mammals such as man and domestic animals.
- Domestic animals include bovine, ovine, porcine, equine, caprine, domestic fowl, Leporidate e.g., rabbits, or other animal which may be held in captivity or may be a vector for a disease affecting a domestic animal such as a marine mammal.
- the purified vaccine solution is prepared for administration to mammals by methods known in the art, which can include filtering to sterilize the solution, diluting the solution, adding an adjuvant and stabilizing the solution.
- the vaccine can be lyophilized to produce a vaccine against brucellae in a dried form for ease in transportation and storage.
- the vaccine may be prepared in the form of a mixed vaccine which contains the deletion strains as described above and at least one other antigen as long as the added antigen does not interfere with the effectiveness of the vaccine and the side effects and adverse reactions are not increased additively or synergistically.
- the vaccine may be stored in a sealed vial, ampule or the like.
- the present vaccine can generally be administered in the form of a liquid or suspension. In the case where the vaccine is in a dried form, the vaccine is dissolved or suspended in sterilized distilled water before administration.
- the vaccine may be administered orally, subcutaneously, intradermally or intramuscularly but preferably intranasally in a dose effective for the production of neutralizing antibody and protection from infection or disease.
- the manner of application of the vaccines may be varied widely, any of the conventional methods for administering a live vaccine being applicable. These include, orally, on a solid physiologically acceptable base, or in a physiologically acceptable dispersion.
- the dosage of the vaccine (number of bacteria, number of administrations) will depend on route of administration and will vary according to the species to be protected.
- the dosage of administered agent will vary depending upon such factors as the route of administration, patient's species, age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage of the above compounds which is in the range of from about 10 cfu/kg to 10 6 cfu/kg (body weight of patient), although a lower or higher dosage may be administered.
- administration of live bacteria can be by intramuscular injection of by feeding in doses which are safe and may be appropriate.
- heifers can be injected subcutaneously in the axillary area with 1-1.4 ⁇ 10 10 cfu [Cheville, N. F. et al. (1993) Am. J. Vet. Res. 54:1591-1597].
- One or more additional administrations may be provided as booster doses, usually at convenient intervals such as two to three weeks.
- the present invention related to a method and composition for delivering antigens or genes into cells.
- One or more of the desired antigens, or genes coding for these antigens can be introduced into the live brucellae strains described above for use as a vaccine, and can be used only to provide said antigen, i.e. as a delivery vehicle, or to provide protection as a vaccine and deliver the desired antigen.
- the desired gene or antigen can be introduced into the bacteria either as episomal DNA, or as part of the Brucella chromosome by recombination for example, advantageously inserted in the deletion site of the vaccine strain, or replacing the selectable marker used in selecting the vaccine strain.
- Genes of interest may come from diverse sources, such as bacteria, viruses, fungi, protozoa, metazoan parasites or the like.
- the structural genes may encode envelope proteins, capsid proteins, surface proteins, toxins, such as exotoxins or enterotoxins, or the genes of interest may specify proteins, enzymes, or oligosaccharide antigen or for modification of a saccharide-containing antigen, such as LPS, of the host bacterial strain, or for synthesis of a polypeptide antigen.
- Specific examples of genes of interest include HIV vif, malarial circumsporozoite protein, HBV core protein, and arboviral coat protein, to name a few.
- the construct or vector containing the gene of interest may be introduced into the host strain by any convenient means such as conjugation, transformation, transfection, transduction, etc.
- the Brucella containing the gene or antigen of interest is then allowed to enter the cell by infection, wherein the bacteria can replicate for a limited time thereby providing the antigen or gene of interest inside the cell. Additional administrations of the antigen or gene of interest can occur depending on the amount of antigen desired in the infected cell.
- Bacterial cells were then harvested by centrifuge, washed in sterile 0.9% NaCl, and adjusted to the correct dilution in the same. Turbidity was measured by spectrophotometer (Spectronic 20, Spectronic Instruments, Inc., Rochester, N.Y.) to estimate viable bacterial counts and thus determine the appropriate dose for infection. Actual colony-forming units (CFUs) in the inocula were determined by serial dilution and plating on Brucella agar. Plate counts were made after four days of incubation at 37° C., unless otherwise noted.
- CFUs colony-forming units
- mice Female mice were obtained from Harlan Sprague Dawley, Frederick, Md., and were used at eight to twelve weeks of age. Mice were Brucella-free and were kept in a Biosafety level three (BSL-3) facility. Studies were performed according to Armed Forces Institute of Pathology Regulation 70-1 and all regulations and guidelines regarding the use of laboratory animals in research.
- Brucella melitensis 16M was grown for 20 hours in YENB [Sharma, R. C., and R. T. Schimke (1996) BioTechniques 20:42-44], pelleted, washed in 1 ⁇ 2 volume cold 10% glycerol and resuspended in ⁇ fraction (1/10) ⁇ volume of the same.
- YENB Shield, R. C., and R. T. Schimke (1996) BioTechniques 20:42-44]
- pelleted washed in 1 ⁇ 2 volume cold 10% glycerol and resuspended in ⁇ fraction (1/10) ⁇ volume of the same.
- 1 ⁇ g of plasmid DNA was added to 100 ⁇ of the electrocompetent bacteria and then electroporated at 2.5 kV, 25 ⁇ F and 600 ⁇ .
- One ml of SOC Life Technologies, Inc., Gaithersburg, Md.
- the electroporation mix was then plated on brucella agar containing 10
- Chloramphenicol-resistant electroporants were then screened on brucella agar plates containing 100 ⁇ g/ml ampicillin and on plates with 5 ⁇ g/ml chloramphenicol and 50 ⁇ g/ml ampicillin. Ampicillin-sensitive, chloramphenicol-resistant colonies were then tested for changes in LPS first by staining with crystal violet and then by agglutination with anti-brucellar LPS serum. The chromosomes of these transformants were isolated [Marmur, J. (1961) J. Mol. Biol. 3:208-218] and examined by Southern hybridization.
- Chromosomal DNA preparations were digested with EcoRI and ClaI, electroporated on a 1% agarose slab gel in TAE buffer, and transferred in a positive pressure cell (Stratagene, LaJolla, Calif.) to a Nytran membrane (Schleicher and Schuell, Keene, N.H.).
- An rfbU probe was made by DNA amplification via the polymerase chain reaction (PCR) using oligonucleotide primers with the nucleotide sequences 5′-GGATGTCGACCCAGCCCTCCACATCAATAGC-3′ (SEQ ID NO:3) and 5′-TTGCGGATCCTTTACTCGTCCGTCTCTTAC-3′ (SEQ ID NO:4).
- PCR polymerase chain reaction
- melitensis 16M DNA served as template.
- the amplicon contained the rfbU gene, 606 bp of the upstream flank and 278 bp of the downstream flank.
- the probe was labeled nonisotopically (Amersham Life Sciences, Birminghamshire, England) and hybridised at 42° C.
- B. melitensis strain WRRP1 was constructed by electroporating WRR51 with pURE198 [Drazek et al. (1995) Infect. Immun. 63:3297-3301]. Electroporants with resistance to kanamycin (50 ⁇ g/ml) and chloramphenicol (5 ⁇ g/ml) were selected on brucella agar plates and then replica plated on brucella agar containing 100 ⁇ g/ml ampicillin, M9 minimal media agar and M9 agar with added purines (5 mM adenine, 0.3 mM guanine). Recombinational replacement of the purE locus with ⁇ purE198 was confirmed by Southern hybridisation.
- Chromosomal preparations were digested with EcoRI and HindIII and probed with a PCR amplification product that included most of the purEK operon (GenBank locus BMU10241) and was made using the oligonucleotide primers 5′-CACCATGCAGCCGACACA-3′ (SEQ ID NO:5) and 5′-CCGCGCCGCAGATTCAGG-3′ (SEQ ID NO:6). Maintainance of the ⁇ rfbU5.1 mutation in WRRP1 was also verified by Southern blot.
- Broth media did not contain antibiotics to avoid carryover; cultures used to infect were plated selective and nonselective agar to verify that antibiotic resistance was maintained uniformly in strains which bear these markers.
- brucellae were resuspended to 2 ⁇ 10 8 CFU/ml in saline and added to MDM wells at a multiplicity of infection of 10:1. Infections proceeded for 60 min. at 37° C., then monolayers were washed three times with RPMI with 10% Sigma serum and 2 mM L-glutamine. MDM medium with 1 ⁇ g/ml gentamycin was then added to wells and plates were incubated at 37° C. in a 5% CO 2 incubator.
- mice survival in mice. Groups of mice were inoculated intraperitoneally with various doses of B. melitensis 16M and of the mutants, or with 0.2 ml sterile saline in the case of the control group. Blood, spleens, liver and lungs were obtained from the infected and control mice at 3, 7, 14, 42, 56 and 84 days after infection. Three mice from each group were sampled at each timepoint. Organs were weighed and then homogenized with 1 ml sterile saline. Suspensions were then diluted in sterile saline and plated on brucella agar. Colonies of Brucella were counted after 4 days of incubation at 37° C., and then again after 6 days for slow-growing strains. The identity of recovered colonies was confirmed by screening for antibiotic resistance and relevant phenotype.
- the B. abortus gene containing the Tn5 insertion was first cloned from the VTRA1 chromosome on an 11.6 kbp DNA fragment in the plasmid construct pJM63. From a number of subclones of the pJM63 insert, the nucleotide sequence of the 2693 bp region containing the transposon insertion was determined (SEQ. ID. NO: 1). The Tn5 insertion was located within an open reading frame of 1233 bp which coded for a gene that was distantly related (40% amino acid similarity) to the sequence of the Salmonella enterica LT2 RfbU.
- a deletion of 607 bp was made in the putative rfbU gene of pJM63 using ClaI restriction sites at nucleotide positions 1063 and 1670 in the DNA sequence.
- a 1053 bp cassette containing a chloramphenicol acetyl transferase gene (cat) was ligated into the deletion site to create the plasmid pRFBU1.
- pRFBU1 was electroporated into B. melitensis strain 16M and electroporants with pRFBU1 integrated were selected on Brucella agar containing chloramphenicol.
- Resistant colonies were then screened for the loss of ampicillin resistance, which indicated that the vector portion of pRFBU1 had been lost from the chromosome by a second crossover recombinational event.
- DNA hybridization confirmed that the chloramphenicol resistant and ampicillin sensitive electroporants had the deletion mutation carrying the chloramphenicol resistance cassette in place of the wild type chromosomal locus.
- the deletion strain, designated WRR51 was confirmed to be rough by staining with crystal violet and by lack of agglutination with an anti-LPS serum.
- a purE deletion was then introduced into B. melitensis strain WRR51 by a similar allelic exchange procedure.
- the suicide vector pURE201 was used as previously described [Drazek, E. S. et al. (1995) Infect. Immun. 63:3297-3301] to replace the wild type purE locus with a deleted allele with a kanamycin resistance cassette inserted in the deletion site.
- the resultant double deletion strain ( ⁇ rfbU ⁇ purE) was designated WRRP1.
- mice were infected intraperitoneally with 10 5 brucellae and spleen counts were taken at timepoints over 12 weeks (FIG. 2).
- Wild type B. melitensis 16M persisted in the spleens of infected mice for the full 12 weeks, increasing in count by a log in the first week and then gradually decreasing by about a log over the 11 weeks that followed.
- Spleens of mice infected with double mutant WRRP1 were fully cleared of viable bacteria by one week.
- Rough mutant WRR51 and B. melitensis ⁇ purE 201 persisted in the spleen at eight weeks, but were cleared by 12 weeks.
Abstract
Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of Brucella which results in attenuation of the strain while retaining the desired immunogenicity to initiate a protective immunogenic response. Other strains with varying levels of attenuation are described.
Description
- Brucella infects a significant number of people and livestock in developing countries and infects wild as well as domestic animals in the United States. In addition, Brucella is a potential biowarfare agent; strains of Brucella have been constructed with resistance to multiple antibiotics used to treat the disease. These strains pose a significant morbidity and mortality threat to exposed personnel. Brucellosis symptoms include recurring fever, chills and anxiety. Even though the disease is rarely fatal, once well established, the disease is difficult to treat since the bacteria reside in the bone marrow.
- Two live attenuated Brucella strains currently approved for use as animal vaccines,B. abortus Strain 19 [Cheville, et al. (1993) Am. J. Vet. Res. 54:1591-1597; Brucellosis research: an evaluation. Report of the subcommittee on Brucellosis Research, National Academy of Sciences. Washington, D.C.: National Academy Press, 1977:61-77] and B. melitensis strain Rev 1 [Jimenez de Bagues, M. P. et al. (1989) Ann. Rech. Vet. 20:205-213; Pardon, P. et al. (1990) Ann. Rech. Vet. 21:153-160], are not ideal vaccine strains. Both strains cause vaccinated animals to seroconvert and thus make subsequent serological diagnosis of brucellosis difficult [Jimenez de Bagues, M. P. et al. (1992) Vet. Microbiol. 30:233-241]. Both strains can induce abortion (Jimenez de Bagues, 1989, supra; Corner, L. A. and Alton G. G. (1981) Res. Vet. Sci. 31:342-344] and both can cause disease in humans [Blasco, J. M. and R. Diaz (1993) Lancet 342:805; Young, E. J. (1983) Rev. Inf. Dis. 5:821-842]. A more recent attenuated strain of B. abortus, RB51 [Schurig, G. G. et al. (1991) Vet. Microbiol. 28:171-188], shows more promise as a live vaccine strain. RB51 is a rough strain that confers protection against infection by Brucella, yet does not cause seroconversion [Cheville, N. F. 1993, supra; Jimenez de Bagues, M. P. et al. (1994) Infect. Immun. 62:4990-4996]. However, neither the genetic basis of the RB51 rough mutation nor the basis of attenuation is known. Also, RB51 carries resistance to rifampin, an antibiotic currently used to treat brucellosis.
- Therefore, there is a need for a live attenuated Brucella vaccine strain, with a defined nonreverting genetic mutation, which does not cause seroconversion in the vaccinee, and which does not retain resistance to antibiotics used in the treatment of brucellosis.
- The present invention fulfills the need described above. In this application is described attenuated rough strains of Brucella, containing genetically defined mutations, which will not cause seroconversion. The mutations in these attenuated Brucella strains were created by DNA deletion, the type of mutation least susceptible to genetic reversion and are therefore advantageous as vaccine strains. These vaccines strains do not retain resistance to an antibiotic useful for treatment of brucellosis.
- More specifically, this invention relates to two genetically defined rough mutants ofBrucella melitensis, WRR51 and WRRP1, as candidate strains for a live vaccine against brucellosis. These strains differ from Brucella live vaccines currently used in livestock because they have genetically defined mutations that were created by deleting DNA from the Brucella chromosome. Both strains have a lipopolysaccharide (LPS) defect and thus do not cause the seroconversion that complicates disease screening. Smooth strains currently approved for use in animals are not good candidates for human vaccines because though attenuated, they can still cause disease in humans. One of the vaccine strains of the present invention, WRRP1, is a double deletion mutant that is highly attenuated and is unlikely to cause disease in humans.
- Briefly, the genetically defined rough mutants of Brucella were constructed by using aBrucella abortus VTRA1 chromosome containing a Tn5 insertion which conferred a rough phenotype [Winter, A. J. et al. (1996) Amer. J. Vet. Res. 57:677-683]. The B. abortus gene containing the Tn5 insertion was cloned from the VTRA1 chromosome and the nucleotide sequence of the 2693 bp (SEQ ID NO:1) region containing the transposon insertion was determined. The Tn5 insertion was found to be located within an open reading frame of 1233 bp spanning nucleotides 883 through 2115 of SEQ ID NO:1 which coded for a gene that was distantly related (40% amino acid similarity) to the sequence of the Salmonella enterica LT2 rfbU, a gene encoding a mannosyltransferase [Liu, D. et al. (1993) J. Bacteriol. 175:3408-2414]. A deletion of 607 bp was made in the putative rfbU gene and a cassette containing a chloramphenicol acetyl transferase gene (cat) was ligated into the deletion site to create rfbU/cat. The plasmid containing rfbU/cat, pRFBU1, was electroporated into B. melitensis
strain 16M and electroporants with pRFBU1 integrated were selected on Brucella agar containing chloramphenicol. Southern DNA hybridization confirmed that the chloramphenicol resistant and ampicillin sensitive electroporants had the deletion mutation carrying the chloramphenicol resistance cassette in place of the wild type chromosomal locus resulting from a directed allelic exchange by a double crossover recombinational event. The deletion strain, designated WRR51, was confirmed to be rough by staining with crystal violet, and by lack of agglutination with an anti-LPS serum. - A purE deletion was then introduced intoB. melitensis strain WRR51 by a similar allelic exchange procedure. PurE is an essential enzyme in the purine biosynthetic pathway. The resultant double deletion strain (ΔrfbU ΔpurE) was designated WRRP1. The DNA flanking the transposon insertion was sequenced to determine the open reading frame that had been interrupted to cause the rough phenotype and was found to be rfbU. The complete sequence of Brucella rfbU is described for the first time in this application in SEQ ID NO:1.
- Unlike the rough mutants of the present invention, none of the rough mutants described previously includingB. abortus strain 2308 rfbU mutant, VTRA1, and the VTRA1 transposon mutation integrated into the chromosomes of B. melitensis and Brucella suis by allelic exchange to create VTRM1 and VTRS1, respectively [McQuiston, J. R. et al. (1995) Abstract, CRWAD, November 1995; Winter, A. J. et al. (1996) Am. J. Vet. Res. 57:677-683] contained a defined mutation. In other words, the previously described mutant strains were produced by a transposon insertion which is a random event and can occur at any chromosomal location wherein the mutants of the present invention were produced by a directed allelic exchange to produce a unrevertable, defined deletion in the gene. A plasmid construct containing a synthetic copy of the putative rfbU gene that restored the smooth phenotype to the WRR51 deletion mutant of the present invention, did not restore the smooth phenotype to the VTRA1 transposon mutant. The inability to complement the transposon mutant indicates either that the transposon insertion confers a more general genetic defect in LPS biosynthesis (via a polar effect), or that the VTRA1 strain has additional mutations that affect LPS biosynthesis. The rough mutants of the present invention have a defined, nonreverting, deletion in the putative rfbU gene that was integrated into the chromosome by allelic exchange.
- In order to construct the deletion in a rough strain, several factors had to be considered. The sequence of the flanking DNA (the rfbU gene) extending far enough in either direction of the deletion had to be known to allow for PCR or direct cloning of a large enough region of the Brucella chromosome. In addition, it was important to allow for a deletion of a significant portion of the rfbU gene to inactivate the gene in the first attempt; the actual crossover (allelic exchange) of the ΔrfbU for the wild type was very difficult because it occurred at a very low frequency, and after several trials, it was found that a threshold of at least 500 bp on either side of the deletion was necessary for efficient homologous recombination crossover in the Brucella chromosome. High biocontainment facilities, Biosafety Level 3 (BSL3), were necessary to move the deletion construct back into Brucella to make the mutant. Introducing the deletion construct required development of a more efficient method for electroporating DNA into Brucella than used before.
- Therefore, it is an object of the present invention to provide a rfbU DNA fragment encoding 2693 nucleotides useful as a diagnostic agent.
- It is another object of the present invention to provide an amino acid sequence for RfbU protein encoding 411 amino acids.
- It is another object of the present invention to provide a Brucella rfbU DNA fragment containing a deletion useful in attenuating a Brucella strain.
- It is another object of the invention to provide a recombinant vector comprising a vector and any of the above described DNA fragments.
- It is a further object of the present invention to provide a host cell transformed with any of the above-described recombinant DNA constructs.
- It is another object of the present invention to provide a method for producing RfbU protein which comprises culturing a host cell under conditions such that a recombinant vector comprising a vector and the rfbU DNA fragment is expressed and RfbU protein is thereby produced, and isolating RfbU protein for use as a diagnostic agent.
- It is a further object of the present invention to provide an antibody to the above-described RfbU for use as a diagnostic agent.
- It is yet another object of the invention to provide a Brucella spp. vaccine comprising an attenuated rough Brucella containing a defined deletion in the rfbU gene and effective for the production of antigenic and immunogenic response resulting in the protection of an animal against brucellosis. All of the Brucella which infect humans are highly related, probably biovars of the same species [Corbel, M. J. (1997) Emerging Inf. Dis. 3:213-221]. It is expected that this live vaccine would provide cross protection against other Brucella strains since there is thought to be high homology in the rfbU gene in brucellae [Jimenez de Bagues, M. P. et al. (1994) Infect. and Immun. 62:4990-4996].
- It is a further object of the invention to provide a multivalent Brucella vaccine comprising defined Brucella rfbU mutants from a variety of strains effective for the production of antigenic and immunogenic response resulting in the protection of an animal against infection with brucellae.
- It is yet another object of the present invention to provide a method for the diagnosis of brucellae infection comprising the steps of:
- (i) contacting a sample from an individual suspected of having the infection with antibodies which recognize RfbU protein; and
- (ii) detecting the presence or absence of a complex formed between RfbU and antibodies specific therefor.
- It is yet another object of the present invention to provide a method for the diagnosis of Brucella in a sample using the polymerase chain reaction, said method comprising:
- (i) extracting DNA from the sample;
- (ii) contacting said DNA with
- (a) at least four nucleotide triphosphates,
- (b) a primer that hybridizes to rfbU DNA, and
- (c) an enzyme with polynucleotide synthetic activity,
- under conditions suitable for the hybridization and extension of said first primer by said enzyme, whereby a first DNA product is synthesized with said DNA as a template therefor, such that a duplex molecule is formed;
- (iii) denaturing said duplex to release said first DNA product from said DNA;
- (iv) contacting said first DNA product with a reaction mixture comprising:
- (a) at least four nucleotide triphosphates,
- (b) a second primer that hybridizes to said first DNA, and
- (c) an enzyme with polynucleotide synthetic activity,
- under conditions suitable for the hybridization and extension of said second primer by said enzyme, whereby a second DNA product is synthesized with said first DNA as a template therefor, such that a duplex molecule is formed;
- (v) denaturing said second DNA product from said first DNA product;
- (vi) repeating steps iii-vi for a sufficient number of times to achieve linear production of said first and second DNA products;
- (vii) fractionating said first and second DNA products generated from said rfbU DNA; and
- (viii) detecting said fractionated products for the presence or absence of rfbU in a sample.
- It is yet another object of the present invention to provide a method for the detection of Brucella spp. in a sample which comprises assaying for the presence or absence of rfbU RNA or DNA in a sample by hybridization assays.
- It is a further object of the present invention to provide a diagnostic kit comprising a RfbU antibody and ancillary reagents suitable for use in detecting the presence of brucellae in mammalian tissue or serum.
- It is a further object of the present invention to provide a diagnostic kit comprising primers specific for the amplification of rfbU sequences and ancillary reagents suitable for use in detecting the presence of brucellae in mammalian tissue or serum.
- It is yet an object of the present invention to provide a therapeutic method for the treatment or amelioration of symptoms of brucellosis, said method comprising providing to an individual in need of such treatment an effective amount of sera from individuals immunized with the vaccine strains of the present invention in a pharmaceutically acceptable excipient.
- It is another object of the present invention to provide a means to express antigens of interest as potential therapeutics or vaccines for human and veterinary use. RfbU is usually either cytoplasmic or associated with the inner membrane. When brucellae are lysed within host cells, RfbU and any antigen designed to be expressed with RfbU would then be accessible to the intracellular environment of the cell or host.
- It is another object of the invention to provide an inactivated vaccine produced from the live attenuated Brucella described above. The attenuated Brucella of the present invention can be used in producing inactivated Brucella vaccines. By using an attenuated Brucella, particularly the double mutant which is significantly attenuated, there is a much greater margin of safety in the event that the product is incompletely inactivated. Starting with an attenuated strain is also much safer during the manufacturing phase, and may allow production under lower biocontainment levels. In addition, inactivated attenuated Brucella strains can be used to isolate subunits for subunit vaccines.
- These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description and appended claims, and accompanying drawings where:
- FIG. 1 shows ability of rough mutants to grow within human host cells.
- FIG. 2 shows the ability of rough mutants to infect mice via the intraperitoneal route.
- In one embodiment, the present invention relates to a DNA or cDNA segment which encodes RfbU, a mannosyltransferase. The sequence of the gene, specified in SEQ ID NO:1, was obtained by cloning out aBrucella abortus VTRA1 chromosome containing a Tn5 transposon and sequencing the subclones to determine the insertion site of Tn5 in the VTRA1 chromosome. The sequenced gene fragment comprising 2693 base pairs contains an open reading frame of 1233 base pairs.
- DNA or polynucleotide sequences to which the invention also relates include sequences of at least about 6 nucleotides, preferably at least about 8 nucleotides, more preferably at least about 10-12 nucleotides, most preferably at least about 15-20 nucleotides corresponding, i.e., homologous to or complementary to, a region of the rfbU nucleotide sequence. Preferably, the sequence of the region from which the polynucleotide is derived is homologous to or complementary to a sequence which is unique to the rfbU gene. Whether or not a sequence is unique to the rfbU gene can be determined by techniques known to those of skill in the art. For example, the sequence can be compared to sequences in databanks, e.g., GenBank and compared by DNA:DNA hybridization. Regions from which typical DNA sequences may be derived include but are not limited to, for example, regions encoding specific epitopes, as well as non-transcribed and/or non-translated regions.
- DNA sequences also embodied in the present invention include the rfbU sequence containing a deletion. The exemplified deletion described below in the Examples is 607 base pairs in length, spanning from position 1063 to position 1670 of the DNA sequence identified in SEQ. ID. NO:1 and was chosen because of conveniently located restriction sites. Other deletions of any size can be introduced into the rfbU gene for different purposes. In the case where RfbU function is to be eliminated, a deletion large enough to eliminate any possibility of recombinational restoration of gene function is preferable. The deletion need not be framed by restriction sites and can be introduced by PCR, for example. However, cloned homologous DNA of about 500 base pairs flanking the deletion site is necessary for efficient allelic replacement. Methods for manupulating genes in Brucella are known in the art, please see e.g., Maniatis, Fritsch and Sambrook,Molecular Cloning: a Laboratory Manual (1982) or DNA Cloning, volumes I and II (D. N. glover ed. 1985) or Current Protocols in Molecular Biology, Ausubel, F. M. et al. (Eds.) John Wiley & Sons, Inc., for general cloning methods.
- The derived polynucleotide is not necessarily physically derived from the nucleotide sequence shown in SEQ ID NO:1, but may be generated in any manner, including for example, chemical synthesis or DNA replication or reverse transcription or transcription, which are based on the information provided by the sequence of bases in the region(s) from which the polynucleotide is derived. In addition, combinations of regions corresponding to that of the designated sequence may be modified in ways known in the art to be consistent with an intended use. The sequences of the present invention can be used in diagnostic assays such as hybridization assays and polymerase chain reaction assays and for the discovery of other rfbU sequences.
- In another embodiment, the present invention relates to a recombinant DNA molecule that includes a vector and a DNA sequence as described above. The vector can take the form of a plasmid, such as pUC19, or any other vector which replicates inE. coli, or a suicide vector, or broad host range vectors for example pTh10(IncP), pSa(IncW) and R751(IncP) [Rigby, C. E. and A. D. E. Fraser (1989) Can. J. Vet. Res. 53:326-330] and others known in the art.
- In a further embodiment, the present invention relates to host cells stably transformed or transfected with the above-described recombinant DNA constructs. The host cell can be any Brucella or other host cell for which the vector is designed. The vector containing the rfbU gene is expressed in the bacteria and the product can be isolated for use in diagnostic assays. For example, the plasmid pRFBU1, described below in Materials and Methods, containing the rfbU/cat construct can be electroporated into other brucellae, and by allelic exchange with the wild type form of rfbU, can attenuate the electroporants. Please see e.g., Maniatis, Fitsch and Sambrook,Molecular Cloning; A Laboratory Manual (1982) or DNA Cloning, Volumes I and II (D. N. Glover ed. 1985) for general cloning methods. The DNA sequence can be present in the vector operably linked to a highly purified IgG molecule, an adjuvant, a carrier, or an agent for aid in purification of RfbU protein. The transformed or transfected host cells can be used as a source of DNA sequences described above. When the recombinant molecule takes the form of an expression system, the transformed or transfected cells can be used as a source of the protein described below.
- In another embodiment, the present invention relates to a RfbU protein having an amino acid sequence corresponding to SEQ ID NO:2 and encompassing 411 amino acids or any allelic variation thereof.
- A polypeptide or amino acid sequence derived from the amino acid sequence in SEQ ID NO:2, refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 2-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.
- A recombinant or derived polypeptide is not necessarily translated from a designated nucleic acid sequence, or the sequence in SEQ ID NO:1; it may be generated in any manner, including for example, chemical synthesis, or expression of a recombinant expression system. In addition the polypeptide can be fused to other proteins or polypeptides for example, any protective antigen of any pathogen, bacterial or viral for secretion of heterologous antigens from within the host cell since RfbU is either cytoplasmic or associated with the inner membrane. In addition, the protein or polypeptide can be fused to other proteins or polypeptides which increase its antigenicity, thereby producing higher titers of neutralizing antibody when used as a vaccine. Examples of such proteins or polypeptides include any adjuvants or carriers safe for human use, such as aluminum hydroxide.
- In another embodiment, the present invention relates to antibodies specific for the above-described RfbU protein. For instance, an antibody can be raised against the complete RfbU protein or against a portion thereof. Persons with ordinary skill in the art using standard methodology can raise monoclonal and polyclonal antibodies to the polypeptide of the present invention. Material and methods for producing antibodies are well known in the art (see for example Goding, in,Monoclonal Antibodies: Principles and Practice, Chapter 4, 1986).
- In a further embodiment, the present invention relates to a method for detecting the presence of brucellosis infection or antibodies against Brucella in a sample. Using standard methodology well known in the art, a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), all or a unique portion of the RfbU protein, or alternatively, inactivated attenuated Brucella described above, and contacting it with the serum of a person suspected of having a brucellosis infection. The presence of a resulting complex formed between the antigen (RfbU or attenuated Brucella) and antibodies specific therefor in the serum can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colorimetry. This method of detection can be used, for example, for the diagnosis and typing of brucellosis infections.
- In yet another embodiment, the present invention relates to a method of detecting the presence of Brucella in a sample. Using standard methodology well known in the art, a diagnostic assay can be constructed by coating on a surface (i.e. a solid support) for example, a microtitration plate or a membrane (e.g. nitrocellulose membrane), antibodies specific for RfbU, and contacting it with serum or tissue sample of a person suspected of having a brucellosis infection. The presence or absence of a resulting complex formed between RfbU in the serum or presented on antigen presenting cells and antibodies specific therefor can be detected by any of the known methods common in the art, such as fluorescent antibody spectroscopy or colorimetry. This method of detection can be used, for example, for the diagnosis of a brucellosis infection or for typing the specific Brucella bacteria causing such an infection.
- In another embodiment, the present invention relates to a diagnostic kit which contains RfbU from a specific strain or species of Brucella or several different strains and species of Brucella and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence of antibodies to Brucella in serum or a tissue sample. Tissue, blood, serum, or urine samples contemplated can be animal, in particular abortion products of large animals, or human, or other vertebrates. Other samples contemplated include dairy products, especially unpasturized products, from which the disease is most frequently contracted.
- In yet a further embodiment, the present invention relates to DNA or nucleotide sequences for use in detecting the presence or absence of Brucella using the polymerase chain reaction (PCR). Since rfbU is probably very similar at the DNA level across all Brucella, the DNA sequence of the present invention can be used to design primers which specifically bind to the rfbU DNA for the purpose of detecting the presence, absence, or quantitating the amount of Brucella. The primers can be any length ranging from 7-40 nucleotides, preferably 10-15 nucleotides, most preferably 18-25 nucleotides. Reagents and controls necessary for PCR reactions are well known in the art. The amplified products can then be analyzed for the presence or absence of rfbU sequences, for example by gel fractionation, with or without hyridization, by radiochemistry, and immunochemical techniques. This method can also be used for typing a brucellosis infection.
- In yet another embodiment, the present invention relates to a diagnostic kit which contains PCR primers specific for rfbU, and ancillary reagents that are well known in the art and that are suitable for use in detecting the presence or absence of Brucella in a sample using PCR. Samples contemplated can be human or other mammals, dairy products, blood, urine, tissues, depending on the stage of infection. Early infection tissues would include lungs and the lymphatic system, late infection tissues would include spleen, liver, and kidneys, and later infection tissues would include bone marrow and absesses in organs and brain.
- In another embodiment, the present invention can be used to diagnose Brucella infection by using the DNA sequences for detecting the presence or absence of rfbU in a DNA sample using hybridization assays such as Southern hybridization or the expression of rfbU gene, or rfbU RNA, by northern hybridizations and other hybridization assays well known to a person with ordinary skill in the art.
- In another embodiment, the present invention relates to a vaccine for protection against infections by Brucella. The vaccine comprises one or more attenuated rough Brucella strains containing a defined deletion, for example, in the rfbU gene. The deletion in the rfbU gene can be introduced by allelic exchange due to a double cross-over recombinational event, or any other method wherein a DNA replacement event in which two separate DNA recombination events result in the exchange of a piece of the intact gene for a homologous piece containing a deletion. The deletion is preferably large enough such that the gene is inactivated in the first attempt and to reduce the likelihood of a recombinational repair. Other genes which can be deleted include purE, dnaKJ, recA, groELS, catalase, or any other gene which contributes to survival in human macrophages and/or to bacterial virulence. Any strain of Brucella can be used to introduce such an attenuating mutation. The resulting attenuated strain can be tested for the deletion of the targetted gene by methods known in the art such as Southern blot hybridization, and the level of attenuation tested in a mouse model as described in the Examples below. Any deletion in the rfbU gene would result in the attenuation of the bacteria unless the deletion was small and allowed for functional rfbU expression. Any deletion which inactivates the rfbU gene expression or blocks function of its gene product will be both rough and attenuated.
- For example, as described below in more detail, a deletion in the rfbU gene ofBrucella melitensis was introduced by allelic exchange with a copy of the rfbU gene present on a vector. The rfbU gene to be exchanged with the wild type version contained a deletion into which a chloramphenicol acetyl transferase gene was cloned. Once the vector was introduced into B. melitensis, by electroporation in this example, a double cross-over recombinational event occured such that the vector rfbU gene containing the deletion, was exchanged for the chromosomal wild type rfbU. The resulting B. melitensis strain WRR51 contained a defined mutation was rough and attenuated, and did not possess resistance to an antibiotic used to treat brucellosis.
- In another embodiment of the invention, the Brucella having the deletion in the rfbU gene as described above additionally contains another deletion in a different gene. The advantage of having two deletions is to further reduce the possibility of reversion, and to additionally attenuate the bacteria. However, for use as a live vaccine a certain amount of replication is necessary in the host. Therefore, any vaccine strain designed in the methods of the present invention must be tested for its ability to survive in the host. These tests can be done in vitro, for example in a monocyte-derived macrophages system as described below in the Examples, or, as a second step, in non-human primates. It is preferable that the bacteria persists in the host for sufficient time to elicit a strong immunogenic response, for example from about four to six weeks. Bacteria too attenuated to survive enough to elicit an immunogenic response can be useful as diagnostic agents.
- In the specific examples described below, a deletion in the purE gene ofB. melitensis WRR51 was introduced using the allelic exchange procedure described above. The wild type purE locus was replaced with a deleted allele with a kanamycin resistance cassette inserted in the deletion site. The resultant double deletion strain (ΔrfbU ΔpurE) was designated WRRP1. Other genes which can be used for introducing a second deletion include, but are not limited to e.g. dnaKJ, recA, genes potentially contributing to intracellular survival and proliferation (replication), for example by studying genes homologous to those found important in other intracellular bacterial pathogens or by screening for important genes for brucellar intracellular survival directly using IVET, or in vivo expression technology [Mahan, M. J. et al. (1993) Science 259:686-688].
- Both the single deletion strain, WRR51, and the double deletion strain, WRRP1, were tested in human-derived macrophages and were found able to infect human monocytes, and had reduced capacity to grow within host cells. WRRP1, the double deletion, appeared to lose viability in host cells at a more rapid rate than those with a single deletion mutation such as WRR51, (ΔrfbU), orB. melitensis ΔpurE. Thus, the subject strains should be able to persist in the host for extended periods of time, usually weeks, to enhance the effectiveness of the immunizing effect by continuous stimulation of the host immmune system until the host immune system has cleared all the organisms.
- Ideally, for human administration, the vaccine strains should be sensitive to all antibiotics and synthetic antibacterials which are active against strains of Brucella. Even though strains containing these markers can be used as animal vaccines, it is preferable that strains selected on the basis of a selectable markers such as cat or kanamycin be further manipulated to remove these selectable markers. Methods for removing the marker gene include use of a “toxic” gene in vector as counterselectable marker to insure double crossover event e.g. sacB. These markers would be removed by a second allelic exchange, homologous recombination, this time with a copy of the gene containing the same deletion, but without the antibiotic resistance cassette inserted and verified by phenotype screening and Southern blot analysis. It is preferable to avoid providing resistance genes that can be disseminated through the environment or within the host to other pathogens.
- The subject vaccines may be used in a wide variety of vertebrates. The subject vaccines will find particular use with mammals such as man and domestic animals. Domestic animals include bovine, ovine, porcine, equine, caprine, domestic fowl, Leporidate e.g., rabbits, or other animal which may be held in captivity or may be a vector for a disease affecting a domestic animal such as a marine mammal.
- The purified vaccine solution is prepared for administration to mammals by methods known in the art, which can include filtering to sterilize the solution, diluting the solution, adding an adjuvant and stabilizing the solution. The vaccine can be lyophilized to produce a vaccine against brucellae in a dried form for ease in transportation and storage. Further, the vaccine may be prepared in the form of a mixed vaccine which contains the deletion strains as described above and at least one other antigen as long as the added antigen does not interfere with the effectiveness of the vaccine and the side effects and adverse reactions are not increased additively or synergistically.
- The vaccine may be stored in a sealed vial, ampule or the like. The present vaccine can generally be administered in the form of a liquid or suspension. In the case where the vaccine is in a dried form, the vaccine is dissolved or suspended in sterilized distilled water before administration. Generally, the vaccine may be administered orally, subcutaneously, intradermally or intramuscularly but preferably intranasally in a dose effective for the production of neutralizing antibody and protection from infection or disease. The manner of application of the vaccines may be varied widely, any of the conventional methods for administering a live vaccine being applicable. These include, orally, on a solid physiologically acceptable base, or in a physiologically acceptable dispersion. The dosage of the vaccine (number of bacteria, number of administrations) will depend on route of administration and will vary according to the species to be protected.
- When providing a patient with live bacteria vaccines, the dosage of administered agent will vary depending upon such factors as the route of administration, patient's species, age, weight, height, sex, general medical condition, previous medical history, etc. In general, it is desirable to provide the recipient with a dosage of the above compounds which is in the range of from about 10 cfu/kg to 106 cfu/kg (body weight of patient), although a lower or higher dosage may be administered. For calves, for example, administration of live bacteria can be by intramuscular injection of by feeding in doses which are safe and may be appropriate. For example, at 10 months of age, heifers can be injected subcutaneously in the axillary area with 1-1.4×1010 cfu [Cheville, N. F. et al. (1993) Am. J. Vet. Res. 54:1591-1597]. One or more additional administrations may be provided as booster doses, usually at convenient intervals such as two to three weeks.
- In another embodiment, the present invention related to a method and composition for delivering antigens or genes into cells. One or more of the desired antigens, or genes coding for these antigens, can be introduced into the live brucellae strains described above for use as a vaccine, and can be used only to provide said antigen, i.e. as a delivery vehicle, or to provide protection as a vaccine and deliver the desired antigen. The desired gene or antigen can be introduced into the bacteria either as episomal DNA, or as part of the Brucella chromosome by recombination for example, advantageously inserted in the deletion site of the vaccine strain, or replacing the selectable marker used in selecting the vaccine strain. Genes of interest may come from diverse sources, such as bacteria, viruses, fungi, protozoa, metazoan parasites or the like. The structural genes may encode envelope proteins, capsid proteins, surface proteins, toxins, such as exotoxins or enterotoxins, or the genes of interest may specify proteins, enzymes, or oligosaccharide antigen or for modification of a saccharide-containing antigen, such as LPS, of the host bacterial strain, or for synthesis of a polypeptide antigen. Specific examples of genes of interest include HIV vif, malarial circumsporozoite protein, HBV core protein, and arboviral coat protein, to name a few. The construct or vector containing the gene of interest may be introduced into the host strain by any convenient means such as conjugation, transformation, transfection, transduction, etc. The Brucella containing the gene or antigen of interest is then allowed to enter the cell by infection, wherein the bacteria can replicate for a limited time thereby providing the antigen or gene of interest inside the cell. Additional administrations of the antigen or gene of interest can occur depending on the amount of antigen desired in the infected cell.
- Described below are examples of the present invention which are provided only for illustrative purposes, and not to limit the scope of the present invention. In light of the present disclosure, numerous embodiments within the scope of the claims will be apparent to those of ordinary skill in the art.
- The following MATERIALS AND METHODS were used in the examples that follow.
- Strains and growth conditions. All Brucella strains were grown in brucella broth or agar or M9 minimal agar.B. melitensis strains 16M (wild type), ΔpurE201 [Drazek et al. (1995) Infect. Immun. 63:3297-3301], WRR51 and
WRRP 1 were used to infect both monocyte-derived macrophages (MDMs) and mice. Stocks of exponential-phase cultures frozen in 20% glycerol were thawed and used to inoculate. Broth cultures were shaken at 37° C. for 22 to 26 hours until an A600 of 0.4 to 0.6 was obtained. Bacterial cells were then harvested by centrifuge, washed in sterile 0.9% NaCl, and adjusted to the correct dilution in the same. Turbidity was measured by spectrophotometer (Spectronic 20, Spectronic Instruments, Inc., Rochester, N.Y.) to estimate viable bacterial counts and thus determine the appropriate dose for infection. Actual colony-forming units (CFUs) in the inocula were determined by serial dilution and plating on Brucella agar. Plate counts were made after four days of incubation at 37° C., unless otherwise noted. - Animals. BALB/C female mice were obtained from Harlan Sprague Dawley, Frederick, Md., and were used at eight to twelve weeks of age. Mice were Brucella-free and were kept in a Biosafety level three (BSL-3) facility. Studies were performed according to Armed Forces Institute of Pathology Regulation 70-1 and all regulations and guidelines regarding the use of laboratory animals in research.
- Construction ofB. melitensis rough mutants. The DNA sequence of pJM63 [Winter, A. J. et al. (1996) Amer. J. Vet. Res. 57:677-683] flanking the Tn5 insertion in the putative rfbU gene of B. abortus 2303 was obtained. The rfbU gene was subcloned, and two ClaI sites were used to delete an internal portion of the gene (between positions 1063 and 1670) containing the Tn5 insertion, to create pJM83ΔClaI. A chloramphenicol resistance cassette was then place into the ClaI deletion site to make the mutator plasmid pRFBU1.
Brucella melitensis 16M was grown for 20 hours in YENB [Sharma, R. C., and R. T. Schimke (1996) BioTechniques 20:42-44], pelleted, washed in ½ volume cold 10% glycerol and resuspended in {fraction (1/10)} volume of the same. Incuvettes 1 μg of plasmid DNA was added to 100 μof the electrocompetent bacteria and then electroporated at 2.5 kV, 25 μF and 600 Ω. One ml of SOC (Life Technologies, Inc., Gaithersburg, Md.) was added and the mix was incubated at 37° C. with shaking for one hour. The electroporation mix was then plated on brucella agar containing 10 μg chloramphenicol per ml. - Chloramphenicol-resistant electroporants were then screened on brucella agar plates containing 100 μg/ml ampicillin and on plates with 5 μg/ml chloramphenicol and 50 μg/ml ampicillin. Ampicillin-sensitive, chloramphenicol-resistant colonies were then tested for changes in LPS first by staining with crystal violet and then by agglutination with anti-brucellar LPS serum. The chromosomes of these transformants were isolated [Marmur, J. (1961)J. Mol. Biol. 3:208-218] and examined by Southern hybridization. Chromosomal DNA preparations were digested with EcoRI and ClaI, electroporated on a 1% agarose slab gel in TAE buffer, and transferred in a positive pressure cell (Stratagene, LaJolla, Calif.) to a Nytran membrane (Schleicher and Schuell, Keene, N.H.). An rfbU probe was made by DNA amplification via the polymerase chain reaction (PCR) using oligonucleotide primers with the nucleotide sequences 5′-GGATGTCGACCCAGCCCTCCACATCAATAGC-3′ (SEQ ID NO:3) and 5′-TTGCGGATCCTTTACTCGTCCGTCTCTTAC-3′ (SEQ ID NO:4). B. melitensis 16M DNA served as template. The amplicon contained the rfbU gene, 606 bp of the upstream flank and 278 bp of the downstream flank. The probe was labeled nonisotopically (Amersham Life Sciences, Birminghamshire, England) and hybridised at 42° C.
- Genetic complementation was used to confirm that the ΔrfbU 5.1 mutation caused the LPS defect in WRR51. The amplicon described above that contained an intact copy of rfbU was cloned into pBBR1MCS and the resultant construct was electroporated into WRR51. Presence of the plasmid in electroporants was verified by antibiotic selection and by plasmid isolation and analysis. WRR51 electroporants bearing the rfbU plasmid were tested for restoration of wild type LPS synthesis by crystal violet staining and by anti-LPS agglutination.
-
- Procedures not specified above were done by standard methodology [Ausubel et al. (ed.) 1994. Current protocols in molecular biology. Greene Publishing Associates, New York; and Sambrook et al. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, N.Y.].
- Human MDM infection. Mononuclear cells obtained by centrifuging leukopaks from normal donors over lymphocyte separation medium (Organon Teknika, Durham, N.C.). Counterflow centrifugal elutriation was then used to further purify the monocytes [L. M. Wahl et al. (1984)Cell. Immunol. 85:373-383], resulting in preparations with greater than 95% viability (estimated by trypan exclusion) and <10% lymphocytes. Monocytes were suspended in MDM medium [RPMI 1640 medium (Life Technologies, Inc., Gaithersburg, Md.) with 10% heat-inactivated human serum (Sigma Chemical Co., St. Louis, Mo.), 2 mM L-glutamine and 10 ng/ml of recombinant human macrophage colony stimulating factor (Jay Stoudemire, Genetics Institute, Boston, Mass.)]. This suspension was added to wells in a sterile tissue culture plate and 105 cells per well were cultured as adherent monolayers at 37° C. in a 5% CO2 incubator. On the fourth day and again on the seventh day, half of the medium was removed and replaced with fresh medium. On the eighth day of the experiment, the media in the MDM culture wells was removed and replaced with the medium described above, except with 10% unheated normal serum in place of Sigma serum. Brucella strains were grown as stated above. Broth media did not contain antibiotics to avoid carryover; cultures used to infect were plated selective and nonselective agar to verify that antibiotic resistance was maintained uniformly in strains which bear these markers. After the saline wash, brucellae were resuspended to 2×108 CFU/ml in saline and added to MDM wells at a multiplicity of infection of 10:1. Infections proceeded for 60 min. at 37° C., then monolayers were washed three times with RPMI with 10% Sigma serum and 2 mM L-glutamine. MDM medium with 1 μg/ml gentamycin was then added to wells and plates were incubated at 37° C. in a 5% CO2 incubator. At various timepoints plates were removed and MDM monolayers were washed as before, and then lysed by adding 0.1% Triton X-100 and mixing vigorously. Lysates were diluted serially in sterile saline, and these dilutions were plated on brucella agar to obtain viable counts. Presented here are mean values from three MDM wells, dilutions from each plated in duplicate. The data shown are representative of at least four different experiments.
- Survival in mice. Groups of mice were inoculated intraperitoneally with various doses of
B. melitensis 16M and of the mutants, or with 0.2 ml sterile saline in the case of the control group. Blood, spleens, liver and lungs were obtained from the infected and control mice at 3, 7, 14, 42, 56 and 84 days after infection. Three mice from each group were sampled at each timepoint. Organs were weighed and then homogenized with 1 ml sterile saline. Suspensions were then diluted in sterile saline and plated on brucella agar. Colonies of Brucella were counted after 4 days of incubation at 37° C., and then again after 6 days for slow-growing strains. The identity of recovered colonies was confirmed by screening for antibiotic resistance and relevant phenotype. - TheB. abortus gene containing the Tn5 insertion was first cloned from the VTRA1 chromosome on an 11.6 kbp DNA fragment in the plasmid construct pJM63. From a number of subclones of the pJM63 insert, the nucleotide sequence of the 2693 bp region containing the transposon insertion was determined (SEQ. ID. NO: 1). The Tn5 insertion was located within an open reading frame of 1233 bp which coded for a gene that was distantly related (40% amino acid similarity) to the sequence of the Salmonella enterica LT2 RfbU. A deletion of 607 bp was made in the putative rfbU gene of pJM63 using ClaI restriction sites at nucleotide positions 1063 and 1670 in the DNA sequence. A 1053 bp cassette containing a chloramphenicol acetyl transferase gene (cat) was ligated into the deletion site to create the plasmid pRFBU1. pRFBU1 was electroporated into
B. melitensis strain 16M and electroporants with pRFBU1 integrated were selected on Brucella agar containing chloramphenicol. Resistant colonies were then screened for the loss of ampicillin resistance, which indicated that the vector portion of pRFBU1 had been lost from the chromosome by a second crossover recombinational event. DNA hybridization confirmed that the chloramphenicol resistant and ampicillin sensitive electroporants had the deletion mutation carrying the chloramphenicol resistance cassette in place of the wild type chromosomal locus. The deletion strain, designated WRR51, was confirmed to be rough by staining with crystal violet and by lack of agglutination with an anti-LPS serum. - A purE deletion was then introduced intoB. melitensis strain WRR51 by a similar allelic exchange procedure. The suicide vector pURE201 was used as previously described [Drazek, E. S. et al. (1995) Infect. Immun. 63:3297-3301] to replace the wild type purE locus with a deleted allele with a kanamycin resistance cassette inserted in the deletion site. The resultant double deletion strain (ΔrfbU ΔpurE) was designated WRRP1.
- Human monocyte-derived macrophages were infected with
B. melitensis 16M, with B. melitensis ΔpurE 201, and with rough mutants WRR51 and WRRP1 (FIG. 1). The wild type parent strain increased over two logs in 72 hours, but the rough mutants decreased in count over the same timecourse. Counts of the rough mutant WRR51 decreased gradually, comparable with levels seen with B. melitensis ΔpurE 201, while the rough purE strain, WRRP1, was reduced by a full log over 72 hours. These results indicated that though the rough mutants were fully able to infect human monocytes, they had a reduced capacity to grow within host cells. WRRP1 appeared to lose viability in host cells at a more rapid rate than WRR51 or B. melitensis ΔpurE 201. - In the murine model, BALB/c mice were infected intraperitoneally with 105brucellae and spleen counts were taken at timepoints over 12 weeks (FIG. 2). Wild
type B. melitensis 16M persisted in the spleens of infected mice for the full 12 weeks, increasing in count by a log in the first week and then gradually decreasing by about a log over the 11 weeks that followed. Spleens of mice infected with double mutant WRRP1 were fully cleared of viable bacteria by one week. Rough mutant WRR51 and B. melitensis ΔpurE 201 persisted in the spleen at eight weeks, but were cleared by 12 weeks. While these strains were similar in the duration of survival in the mouse spleen, early counts of the purE mutant were two logs higher than those of WRR51. This result indicated that the rough mutants are reduced in their efficiency to infect mice, at least by the intrapertoneal route. Both ΔpurE 201 and WRR51 were attenuated relative to the wild type B. melitensis, but both were able to survive in mice for over eight weeks. The double deletion mutant appeared to be severely attenuated compared to either of the single deletion mutants, but recent experiments indicate that increased dosage of WRRP1 can extend its persistence in mice to beyond four weeks. -
1 6 1 2693 DNA Brucella abortus 1 caccttatgt ttgggacatt ttaattagga acgtttatgc 40 cttcggatgc cgtgggcgtg gcatccgcat gagggatggc 80 tttgcgtttc tgcgctttga agatgttgaa attgggttag 120 ggccgcaata tggtggtgta agcctaccag catatgagtt 160 tcgaaatttt gaggggttat ttcttcgccg caccgaagcc 200 actggattgg atggatatac agaccttgga tacgtcccag 240 atgctgaaca gcgggggttc atctttgcag acggagcagc 280 cctccacatc aatagcctgt ttgcagataa taacaagggt 320 gatggcgtgt tttgccaaaa cgtccaatac gtagatggaa 360 acgatctcaa ttcatccatc gacggcggaa ctgggttcaa 400 ttttatcaac gtagatcgca taaacatcaa tacgatccgc 440 agtggtggcc gccggaatat ggcaccagga aatcttaaca 480 ctgtttccca aggtatctct ttgaatgcaa attgtcagac 520 tgtaattata ggcaacgcag ttacccacaa ctggtgaagt 560 cacggttttt atagccaagc tcaggacatt ttggttaatg 600 gtctgatatc acgtgataat ggcggaaggg ggtacgttgc 640 agagggttca gcagggtcat ctctcctaaa tggggccgtt 680 ttcagagata atgtagcagg gaattatttt acaggaggga 720 caagcgtaaa ccatctcgcg aacctccaac ttcataactc 760 tagcaccggg gggaaaactt ttgtggccaa tgtcaccaca 800 aatgggtctg cataacggtc cttgccattt taactataaa 840 tgagctattc ccgcgcatta agagtagaca cgggaaatca 880 gtatggctcc gagacatatt acagttatcc taccagttaa 920 gtaccgaggc ggaagtcttc gagttacgaa gaatatcgtt 960 cgaatgcttt tgaagggaag tcagaattat ggtgaacagt 1000 gtcaagttag attggcagta cgtgccgata cctacgatat 1040 tggggaggag tttcgtgatc ttatcgataa tggtgtagag 1080 gttcgggaaa tatcattcaa agaagttcct ccagaagatg 1120 ttaacaatgc taactatttc caaggtagaa atatcgacct 1160 acagtcgaga acctattggc taatggagga tggccaaaac 1200 aactgtgccg atagtgacct ttggctagtt gtatcctact 1240 ctgtagagta tcctattgcc ccaataaggc cgactctgat 1280 atttgccacc gatttcattc aaaggtacgt acctgatatt 1320 atttggccac cacggcccgg tgagggggat gctgaggctc 1360 ttgcgttctt acgacaatca gacggcgtac tagctacaac 1400 accacacacg cggctggatg cgatttcata cgctggctta 1440 cctgcgtcca aagtttatct tgctccgatg gagtttgacc 1480 cgacgttttt ggatcgttac cggtcagtgt ctaaggttaa 1520 ggaaccctat ttcctttggc caaccaaccc aaatgctcac 1560 aaaaaccatg caaaagcgtt tcaagcgcta gacctatatt 1600 acggcaaact aaagggtaag ataaagacaa agatagtcgg 1640 tgtgagtagt gtgcggatgg acccatccca tcgatggcag 1680 gccaagtacg aaaataaggc ttatgtgaaa tctgtacggg 1720 aaattgttgc gggtctcgac aacctgaaaa gcaatgttga 1760 gttcgctggt gaggttgcgg acaaggagta tgcggagctt 1800 cttgcttcag cttgtttctt ttggcatcca actttggcag 1840 acaacggaac ttttgctgcg gtcgaagcag catatatggg 1880 atgtccaacg ctttcaaacg actacccgca gatgcggtat 1920 atttctaacc gtttcgaaat tcccatgcag tattttaacg 1960 caaggtctgt gaaggaaatg gcatcagcgc ttaagcaaat 2000 ggaggagacg ccaatagatg taggtttatt gccaagtcga 2040 gaaaccctat ctctgcattc gtgggaagct cacgcttccg 2080 aatactggga tgtgatcgtg agggcagcgg catgaataag 2120 ctcggcgtgt ttatcggcta taacccaggc caattagatc 2160 catatcaggg tatttctcgc ttaattgcat tcgtgatcaa 2200 gggggccttg aaccagggta gcggtgtaac aattgcttgc 2240 cccggctggc taaaggacga tgtacgtgtt ctttgggaag 2280 atgctgatat cccacttgaa gcggtcaaaa ttatcgcgac 2320 gaatggtcag cctccattgg cttcgttatg gaagttgaga 2360 gataagttcc gtaagagacg gacgagtaaa cgaaaacgtc 2400 tctggctgga gcgctatgga aaaaatgttg caaattttgt 2440 tgcagaatgg ctttcttcgc gctcgtattg ggggattttt 2480 ttgggggctg ctgcaattgc tgtagtgact attctacttg 2520 ccgtaccaat tgctatagcc ttcaccgctc ttatcggcct 2560 tctatttgct cgtcggctta ttagacgtgt tatcaggtca 2600 aagcttggtt tgttttttca caaaaatgcc aatcaattca 2640 acaaattaat gtcatctgat gaaaccatcg accggatgag 2680 ggaacgggaa ttc 2693 2 410 PRT Brucella abortus 2 Met Ala Pro Arg His Ile Thr Val Ile Leu 5 10 Pro Val Lys Tyr Arg Gly Gly Ser Leu Arg 15 20 Val Thr Lys Asn Ile Val Arg Met Leu Leu 25 30 Lys Gly Ser Gln Asn Tyr Gly Glu Gln Cys 35 40 Gln Val Arg Leu Ala Val Arg Ala Asp Thr 45 50 Tyr Asp Ile Gly Glu Glu Phe Arg Asp Leu 55 60 Ile Asp Asn Gly Val Glu Val Arg Glu Ile 65 70 Ser Phe Lys Glu Val Pro Pro Glu Asp Val 75 80 Asn Asn Ala Asn Tyr Phe Gln Gly Arg Asn 85 90 Ile Asp Leu Gln Ser Arg Thr Tyr Trp Leu 95 100 Met Glu Asp Gly Gln Asn Asn Cys Ala Asp 105 110 Ser Asp Leu Trp Leu Val Val Ser Tyr Ser 115 120 Val Glu Tyr Pro Ile Ala Pro Ile Arg Pro 125 130 Thr Leu Ile Phe Ala Thr Asp Phe Ile Gln 135 140 Arg Tyr Val Pro Asp Ile Ile Trp Pro Pro 145 150 Arg Pro Gly Glu Gly Asp Ala Glu Ala Leu 155 160 Ala Phe Leu Arg Gln Ser Asp Gly Val Leu 165 170 Ala Thr Thr Pro His Thr Arg Leu Asp Ala 175 180 Ile Ser Tyr Ala Gly Leu Pro Ala Ser Lys 185 190 Val Tyr Leu Ala Pro Met Glu Phe Asp Pro 195 200 Thr Phe Leu Asp Arg Tyr Arg Ser Val Ser 205 210 Lys Val Lys Glu Pro Tyr Phe Leu Trp Pro 215 220 Thr Asn Pro Asn Ala His Lys Asn His Ala 225 230 Lys Ala Phe Gln Ala Leu Asp Leu Tyr Tyr 235 240 Gly Lys Leu Lys Gly Lys Ile Lys Thr Lys 245 250 Ile Val Gly Val Ser Ser Val Arg Met Asp 255 260 Pro Ser His Arg Trp Gln Ala Lys Tyr Glu 265 270 Asn Lys Ala Tyr Val Lys Ser Val Arg Glu 275 280 Ile Val Ala Gly Leu Asp Asn Leu Lys Ser 285 290 Asn Val Glu Phe Ala Gly Glu Val Ala Asp 295 300 Lys Glu Tyr Ala Glu Leu Leu Ala Ser Ala 305 310 Cys Phe Phe Trp His Pro Thr Leu Ala Asp 315 320 Asn Gly Thr Phe Ala Ala Val Glu Ala Ala 325 330 Tyr Met Gly Cys Pro Thr Leu Ser Asn Asp 335 340 Tyr Pro Gln Met Arg Tyr Ile Ser Asn Arg 345 350 Phe Glu Ile Pro Met Gln Tyr Phe Asn Ala 355 360 Arg Ser Val Lys Glu Met Ala Ser Ala Leu 365 370 Lys Gln Met Glu Glu Thr Pro Ile Asp Val 375 380 Gly Leu Leu Pro Ser Arg glu Thr Leu Ser 385 390 Leu His Ser Trp Glu Ala His Ala Ser Glu 395 400 Tyr Trp Asp Val Ile Val Arg Ala Ala Ala 405 410 3 31 DNA Brucella melitensis 3 ggatgtcgac ccagccctcc acatcaatag c 31 4 30 DNA Brucella melitensis 4 ttgcggatcc tttactcgtc cgtctcttac 30 5 18 DNA Brucella melitensis 5 caccatgcag ccgacaca 18 6 18 DNA Brucella melitensis 6 ccgcgccgca gattcagg 18
Claims (32)
1. An isolated rfbU DNA fragment or any portion thereof.
2. An isolated and purified DNA fragment according to , wherein said fragment has the sequence of SEQ ID NO:1 or a portion thereof, or an allelic portion thereof.
claim 1
3. An isolated and purified rfbU DNA fragment according to which encodes 411 amino acids or a portion thereof.
claim 2
4. The DNA fragment according to , wherein said DNA fragment encodes the amino acid sequence according to SEQ ID NO:2 or a portion thereof.
claim 3
5. A DNA fragment according to , comprising at least 30 nucleotides of the sequence set forth therein.
claim 3
6. A recombinant DNA construct comprising:
(i) a vector, and
(ii) an isolated and purified rfbU DNA fragment.
7. A recombinant DNA construct according to , wherein said DNA fragment encodes 411 amino acids of RfbU.
claim 6
8. A recombinant DNA construct according to , wherein said rfbU DNA contains a deletion.
claim 6
9. A recombinant DNA construct according to wherein said construct is pRFBU1.
claim 8
10. A recombinant DNA construct according to , wherein said vector is an expression vector.
claim 6
11. The recombinant DNA construct according to , wherein said DNA fragment encodes the amino acids sequence specified in SEQ ID NO:2.
claim 7
12. The recombinant DNA construct according to , wherein said vector is a prokaryotic vector.
claim 6
13. A host cell transformed with a recombinant DNA construct comprising:
(i) a vector, and
(ii) a DNA fragment which encodes 411 amino acids of RfbU, or a portion thereof.
14. A host cell according to , wherein said cell is prokaryotic.
claim 13
15. A host cell according to , wherein said cell is Brucella.
claim 14
16. A host cell according to , wherein said Brucella is Brucella melitensis.
claim 15
17. The host cell of wherein said recombinant DNA construct is pRFBU1.
claim 16
18. The host cell of wherein said cell is WRR51.
claim 17
19. A method for producing RfbU which comprises culturing the cells according to , under conditions such that said DNA fragment is expressed and said RfbU is thereby produced, and isolating said RfbU.
claim 15
20. An antibody to a peptide having the amino acid sequence specified in SEQ ID NO:2, or any portion thereof.
21. A method for the diagnosis of brucellosis infections comprising the steps of:
(i) contacting a sample from an individual suspected of having a brucellosis infection with an antibody according to ; and
claim 20
(ii) detecting the presence or absence of brucellosis by detecting the presence or absence of a complex formed between the RfbU produced as a result of said brucellosis and antibodies specific therefor.
22. A method for the diagnosis of brucellosis infection comprising the steps of:
(i) contacting a sample from an individual suspected of having a brucellosis infection with at least one attenuated strain of Brucella and
(ii) detecting the presence or absence of a brucellosis infection by detecting the presence or absence of a complex formed between the attenuated Brucella and antibodies specific therefor in the sample.
23. A method for detecting rfbU in a sample using the polymerase chain reaction, said method comprising:
(i) extracting DNA from the sample;
(ii) contacting said DNA with
(a) at least four nucleotide triphosphates,
(b) a primer that hybridizes to rfbU DNA, and
(c) an enzyme with polynucleotide synthetic activity,
under conditions suitable for the hybridization and extension of said first primer by said enzyme, whereby a first DNA product is synthesized with said DNA as a template therefor, such that a duplex molecule is formed;
(iii) denaturing said duplex to release said first DNA product from said DNA;
(iv) contacting said first DNA product with a reaction mixture comprising:
(a) at least four nucleotide triphosphates,
(b) a second primer that hybridizes to said first DNA, and
(c) an enzyme with polynucleotide synthetic activity,
under conditions suitable for the hybridization and extension of said second primer by said enzyme, whereby a second DNA product is synthesized with said first DNA as a template therefor, such that a duplex molecule is formed;
(v) denaturing said second DNA product from said first DNA product;
(vi) repeating steps iii-vi for a sufficient number of times to achieve linear production of said first and second DNA products;
(vii) fractionating said first and second DNA products generated from said rfbU DNA; and
(viii) detecting said fractionated products for the presence or absence of rfbU in a sample.
24. A brucellosis infection diagnostic kit comprising an antibody according to and ancillary reagents suitable for use in detecting the presence or absence of RfbU in a mammalian sample.
claim 20
25. A Brucella infection diagnostic kit comprising primers specific for rfbU and ancillary reagents suitable for use in detecting the presence or absence of rfbU in a mammalian sample.
26. A live Brucella vaccine comprising a strain of Brucella wherein said strain contains a deletion in a rfbU gene.
27. A live Brucella vaccine according to wherein said Brucella strain further contains a deletion in a purE gene.
claim 26
28. A live Brucella vaccine according to wherein said Brucella is Brucella melitensis.
claim 26
29. A live Brucella vaccine according to wherein said Brucella is WRR51.
claim 28
30. A live Brucella vaccine according to wherein said Brucella is Brucella melitensis.
claim 27
31. A live Brucella vaccine according to wherein said Brucella is WRRP1.
claim 30
32. A multivalent live Brucella vaccine comprising different strains of Brucella wherein each of the strains contains at least one defined deletion.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/010,877 US6444445B2 (en) | 1998-01-22 | 1998-01-22 | Live vaccine against Brucellosis |
IL13744999A IL137449A0 (en) | 1998-01-22 | 1999-01-21 | Live vaccine against brucellosis |
PCT/US1999/001284 WO1999037783A2 (en) | 1998-01-22 | 1999-01-21 | Live vaccine against brucellosis |
AU24628/99A AU2462899A (en) | 1998-01-22 | 1999-01-21 | Live vaccine against brucellosis |
TR2000/02974T TR200002974T2 (en) | 1998-01-22 | 1999-01-21 | Live vaccine against brucellosis |
IL137449A IL137449A (en) | 1998-01-22 | 2000-07-23 | An isolated brucella dna fragment, a recombinant dna construct containing the same and a method for producing brucella peptide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/010,877 US6444445B2 (en) | 1998-01-22 | 1998-01-22 | Live vaccine against Brucellosis |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010014673A1 true US20010014673A1 (en) | 2001-08-16 |
US6444445B2 US6444445B2 (en) | 2002-09-03 |
Family
ID=21747840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/010,877 Expired - Fee Related US6444445B2 (en) | 1998-01-22 | 1998-01-22 | Live vaccine against Brucellosis |
Country Status (5)
Country | Link |
---|---|
US (1) | US6444445B2 (en) |
AU (1) | AU2462899A (en) |
IL (2) | IL137449A0 (en) |
TR (1) | TR200002974T2 (en) |
WO (1) | WO1999037783A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140248354A1 (en) * | 2010-10-07 | 2014-09-04 | The Texas A&M University System | Controlled release vaccines and methods for treating brucella diseases and disorders |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0212666D0 (en) * | 2002-05-31 | 2002-07-10 | Secr Defence | Immunogenic sequences |
US7416878B2 (en) * | 2002-12-12 | 2008-08-26 | The United States Of America As Represented By The Secretary Of The Army | Immunogenic compositions including rough phenotype Brucella host strains and complementation DNA fragments |
GB0307089D0 (en) * | 2003-03-27 | 2003-04-30 | Secr Defence | Live vaccine strain |
US7364745B2 (en) * | 2004-02-06 | 2008-04-29 | Virginia Tech Intellectual Properties, Inc. | Development of a live, attenuated, recombinant vaccine for Brucellosis |
US20050249755A1 (en) * | 2004-03-03 | 2005-11-10 | Mikeljon Nikolich | Mutant strains of Brucella melitensis and immunogenic compositions |
WO2007028985A2 (en) * | 2005-09-07 | 2007-03-15 | The Secretary Of State For Defence | Adjuvanted vaccine |
GB2453475B (en) * | 2006-07-25 | 2011-01-19 | Secr Defence | Live vaccine strain |
GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
WO2011033129A1 (en) * | 2009-09-21 | 2011-03-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Modified gram-negative bacteria for use as vaccines |
WO2013091040A2 (en) * | 2011-12-22 | 2013-06-27 | Universidade Federal De Minas Gerais - Ufmg | Brucella ovis attenuated strain, vaccine composition and use |
CN103864928A (en) * | 2012-12-13 | 2014-06-18 | 中国农业科学院哈尔滨兽医研究所 | Preparation of common antigen monoclonal antibody of Brucella sLPS (lipopolysaccharides) and establishment of c-ELISA (competitive enzyme-linked immuno sorbent assay)method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643771A (en) | 1980-05-19 | 1997-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Non-reverting live bacterial vaccines |
-
1998
- 1998-01-22 US US09/010,877 patent/US6444445B2/en not_active Expired - Fee Related
-
1999
- 1999-01-21 AU AU24628/99A patent/AU2462899A/en not_active Abandoned
- 1999-01-21 TR TR2000/02974T patent/TR200002974T2/en unknown
- 1999-01-21 IL IL13744999A patent/IL137449A0/en active IP Right Grant
- 1999-01-21 WO PCT/US1999/001284 patent/WO1999037783A2/en active Application Filing
-
2000
- 2000-07-23 IL IL137449A patent/IL137449A/en unknown
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140248354A1 (en) * | 2010-10-07 | 2014-09-04 | The Texas A&M University System | Controlled release vaccines and methods for treating brucella diseases and disorders |
US9248176B2 (en) * | 2010-10-07 | 2016-02-02 | The Texas A&M University System | Controlled release vaccines and methods for treating Brucella diseases and disorders |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11406702B1 (en) | 2020-05-14 | 2022-08-09 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated Salmonella as a vaccine |
Also Published As
Publication number | Publication date |
---|---|
IL137449A0 (en) | 2001-07-24 |
WO1999037783A3 (en) | 2000-02-03 |
WO1999037783A2 (en) | 1999-07-29 |
TR200002974T2 (en) | 2001-01-22 |
AU2462899A (en) | 1999-08-09 |
WO1999037783A9 (en) | 1999-10-14 |
IL137449A (en) | 2007-06-17 |
US6444445B2 (en) | 2002-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3408529B2 (en) | Immunogenic detoxifying variants of cholera toxin and immunogenic detoxifying variants of toxin LT, their preparation and their use for the preparation of vaccines | |
Palmer et al. | A common plasmid of Chlamydia trachomatis | |
Igietseme et al. | Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein–lipophilic immune response-stimulating complexes | |
US6444445B2 (en) | Live vaccine against Brucellosis | |
US20070224217A1 (en) | Virulence genes of M. marinum and M. tuberculosis | |
JPH11137267A (en) | New compound | |
KR20220097391A (en) | Development of a novel live attenuated African swine fever vaccine based on the deletion of gene I177L | |
US5700683A (en) | Virulence-attenuating genetic deletions deleted from mycobacterium BCG | |
MXPA01011477A (en) | Attenuated microorganisms for the treatment of infection. | |
WO1996025519A9 (en) | Virulence-attenuating genetic deletions | |
KR20220009960A (en) | Recombinant Classical Swine Fever Virus | |
Miyamoto et al. | Molecular cloning and sequence analysis of antigen gene tdpA of Treponema denticola | |
US20040110269A1 (en) | Protection against mycobacterial infections | |
AU7383500A (en) | Virulence genes of m. marinum and m. tuberculosis | |
JPH11137275A (en) | New glycogen phosphorylase | |
Nikolich et al. | Attenuation of defined Brucella melitensis wboA mutants | |
US7541447B2 (en) | Process for the preparation of an improved Brucella strain plasmid to develop the strain and the vaccine comprising the said strain | |
JPH09501308A (en) | Regulators of contact-mediated hemolysin | |
WO1999045120A2 (en) | Attenuation of bacteria: materials and methods relating thereto | |
CA2323751A1 (en) | Diagnostics and vaccines for mycobacterial infections of animals and humans | |
MXPA00007236A (en) | Live vaccine against brucellosis | |
US20050249755A1 (en) | Mutant strains of Brucella melitensis and immunogenic compositions | |
AU739191B2 (en) | Vaccines containing attenuated bacteria | |
JPH11243969A (en) | New murd | |
JPH11235183A (en) | Signal recognition particle polypeptide and polynucleotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNITED STATES ARMY, MARYLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NIKOLICH, MIKELJON P.;HOOVER, DAVID L.;WARREN, RICHARD L.;AND OTHERS;REEL/FRAME:012767/0104;SIGNING DATES FROM 20020213 TO 20020301 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
CC | Certificate of correction | ||
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20100903 |